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ABSTRACT
THE ROLE OF STRESS, GLUCOCORTICOIDS & -ADRENERGIC
SIGNALING IN AVERSIVE, HIPPOCAMPUS-DEPENDENT MEMORY
RETRIEVAL
Keith Schutsky
Steven A. Thomas

Studies in wild-type rats and mice, and mutant mice lacking norepinephrine (NE)
demonstrate that NE, 1-adrenergic, cAMP/PKA and Epac signaling are required for
intermediate-term hippocampus-dependent memory retrieval. Although it has been
proposed that glucocorticoids (GCs) facilitate-adrenergic signaling to impair retrieval,
neither a specific requirement for NE nor a definitive mechanism as to how this
interaction occurs has been established. This thesis provides compelling evidence that 1)
GCs do not require (but can synergize with) the adrenergic system to impair
hippocampus-dependent memory retrieval; 2) GCs and xamoterol interact with the 2
receptor to impair retrieval; 3) 2 receptors signal through Gi/o in the hippocampus to
impair retrieval, acting to negate the facilitation of hippocampus-dependent memory
retrieval mediated by 1-Gs signaling; 4) GCs impair retrieval through possibly direct
interaction with the 2 receptor; 5)  signaling is required for retrieval and may be
required for short-term maintenance of fear memory; 6)  signaling influences retrieval;
7) interactions between  receptors are important and net effects of receptor stimulation
(or antagonism) on hippocampal cAMP signaling likely determine the degree of retrieval
impairment expressed, as individual receptors can have similar or opposing effects on
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cAMP levels; and 8) adrenergic and glucocorticoid influences on retrieval are limited by
the age of the memory.
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Chapter 1

Introduction
Keith Schutsky & Steven A. Thomas

Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104
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1.1 Memory Types & Importance of Hippocampus in Episodic Memory
In most circumstances, the ability to learn and remember possesses great adaptive
value, beneficial for an organism’s long-term survival and reproductive success.
Recently, scientists have begun to unravel the molecular and cellular mechanisms
underlying the formation, storage and subsequent recall of both implicit and explicit
memories[1-3]. Implicit memory is a type of long-term memory that doesn't involve
conscious thought. Improvements of penmanship or driving ability by repetition are
examples. Conversely, explicit memory can be defined as the conscious, intentional recall
of past experiences and information. Remembering historical facts or recounting intimate
details from an event from years ago involve this type of memory.
Explicit memory can be further subdivided into semantic and episodic memory.
The former involves "textbook learning" or general factual knowledge about the world. It
enables one to say, without knowing exactly when and where one learned, that George
Washington was our first president, or that Philadelphia is a major city in Pennsylvania.
In contrast, episodic memory involves memory of times, places, associated emotions, and
other contextual knowledge. It allows one to remember what he ate for dinner last night,
who told him that a family member passed away, and where it was he received his first
kiss. Episodic memory is centered in the brain's hippocampus, at least preliminarily[4].
Substantial evidence indicates that the hippocampus is initially required for the
acquisition, consolidation and retrieval of episodic information[4]. However, the
necessity of this structure is thought to dissipate during ―systems consolidation‖, such
that the hippocampus is no longer required for memory retrieval[4]. Support for this
2

comes from hippocampal lesion studies in animals and examination of individuals with
traumatic brain injury, in which bilateral damage to the hippocampus eliminates the
ability to form new episodic memories, as well as impairs the ability to recall recent but
not remote episodic memories[5-7].

1.2 Strength of Memory is Influenced by Environment and Emotional
State
Importantly, the strength of long-term, episodic memory is influenced by the
environment in which it is acquired. Situations of high consequence (i.e. strong positive
or negative outcome for the organism) lead to enhanced emotional arousal and often
result in more rapidly acquired, powerful and/or longer-lasting memories[8, 9]. Enhanced
consolidation from such events is thought to be mediated by neuromodulatory systems,
including the adrenergic & glucocorticoid systems, whose activity correlates with the
valence (―saliency‖) of the situation[10, 11]. For example, individuals learn to associate
with people, places and things that bring them pleasure and strive to avoid those that
cause them pain. In fact, a person’s most vivid episodic memories usually stem from
events filled with emotions ranging from joyful to horrifying. While most of these
memories are beneficial and have adaptive significance, intense, psychologically
terrifying experiences can lead to psychiatric illnesses including post-traumatic stress
disorder (PTSD), a disorder characterized by both the excessive retrieval and enhanced
reconsolidation of traumatic memories[12, 13]. In the past decade, the dramatic increase
in the diagnosis and treatment of PTSD would, in and of itself, serve as a strong impetus
to better understand the molecular and cellular mechanisms underlying episodic memory
recall. However, episodic memory is also believed to be impaired in a multitude of other
3

diseases,

including

depression[14],

dementia[15],

autism[16],

Alzheimer’s[17],

Korsakoff's syndrome[18] and Cushing’s disease[19]. Interestingly, many of these
illnesses are believed to involve alterations in adrenergic signaling[20, 21].

1.3 Animal Models of Fear Memory & Brain Structures Involved
1.3.1 Auditory (Cued) Fear Conditioning
Auditory fear conditioning is form of associative learning considered to be an
example of Pavlovian (classical) fear conditioning. In this behavioral paradigm, rodents
learn to respond defensively to an initially neutral stimulus (the conditioned stimulus;
CS) (e.g. tone) after it has been associated or paired with a harmful stimulus (the
unconditioned stimulus; US) (e.g. footshock). In rodents, presentation of the CS after
conditioning in a distinct context elicits defensive behavior (e.g. freezing). Freezing is a
species-specific response to fear, which is defined as the absence of movement except for
respiration. Intermittent freezing may last for seconds to minutes depending on US
intensity, number of US presentations and the extent of learning achieved by the rodent.
Cued fear is considered to be an implicit form of memory that does not depend on
the hippocampus[22, 23]. Thus, cued fear serves as an excellent paradigm to control for
non-specific effects of drugs that might selectively influence hippocampus-dependent
memory retrieval. The neural underpinnings of cued fear are thought to be localized in
discrete brain regions, some of which are similarly involved in paradigms designed to test
hippocampus-dependent fear memory (1.3.2-1.3.4).
Auditory fear conditioning involves transmission of auditory and somatosensory
information (from the thalamus and cortex) to the lateral nucleus of the amygdala (LA)
4

(the LA is part of the basolateral amygdaloid complex, or BLA), an area that is critical
for fear conditioning and thought to be essential in integrating information about the CS
and US[24]. Electrolytic, excitotoxic or functional inactivation of the LA cause deficits in
the acquisition and expression of auditory fear conditioning[25-27].
Receiving projections from the LA, the central nucleus of the amygdala (CeA) is
required for the acquisition, consolidation and expression of cued fear, demonstrated by
lesion and functional inactivation experiments[28-30]. Most scientists consider the CeA
to be the major output nucleus of a coordinated fear system that acts to carry out a variety
of instinctive, species-specific responses that underlie defensive behaviors[24] and
ablation of the CeA impairs the expression of most CRs, including freezing[24, 31, 32].
1.3.2 Contextual Fear Conditioning
Contextual fear conditioning is a form of Pavlovian conditioning in which an
animal is placed into a novel environment and allowed to explore its surroundings for a
discrete period of time. Then, an aversive stimulus (e.g. US-shock) is administered and
the animal removed. When the animal is placed in the same environment at a later time, it
demonstrates freezing if it has formed a context-US association.
As in auditory fear conditioning, lesions or reversible inactivation of the BLA and
CeA impair the acquisition and expression of contextual fear (CF)[24, 27, 33-36].
Interestingly, the CeA projects to areas of the midbrain periacqueductal gray (PAG),
hypothalamus, and brain stem that orchestrate behavioral, endocrine, and autonomic
conditioned responses (CRs) associated with auditory and contextual fear learning[24].
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Notably, the PAG has been shown to be critical for mediating defensive behavior.
Chemical or electrical stimulation of the dorsal PAG promotes ―flightlike‖ behavior,
while damaging the dPAG attenuates this response. In contrast, chemical or electrical
stimulation of the ventral PAG causes freezing, and pre-training lesions in the vPAG
significantly impair both contextual and auditory fear conditioning [32, 35, 37].
In addition, the dorsal hippocampus (DH) plays a critical role in expression of
contextual fear learning, supported by electrolytic and excitotoxic lesion experiments[22,
38, 39]. Interestingly, electrolytic but not neurotoxic DH lesions impair the acquisition of
context fear[23, 39]. A critical aspect of context fear is that the effect of the DH damage
is time-dependent[24, 31, 39]. If the DH is ablated 1-14 days post-conditioning, rodents
exhibit dramatic deficits in CF expression[24, 31, 39]. On the other hand, if the damage
occurs more than 28 days after training, CF impairment is minimal[24, 31, 39]. A timelimited role for the hippocampus in contextual fear expression mirrors the symptoms of
retrograde amnesia seen in human patients who have experienced hippocampus damage
(e.g. traumatic or anoxic brain injury). Memories acquired just prior to the injury, for
example, are severely impacted, while those acquired several years before are left
essentially intact[4].
Receiving projections from the amygdala, the ventral hippocampus (VH) also
plays an important role in contextual fear conditioning. Electrolytic ablation, excitotoxic
lesions or functional inactivation of the VH inhibit the acquisition and expression of
contextual fear[40-43]. Similarly, the nucleus accumbens (NAcc) and prefrontal cortex
(PFC) influence various aspects of CF[31].
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1.3.3 Inhibitory (Passive) Avoidance
Inhibitory avoidance (IA) is a form of instrumental conditioning in which the
animal learns to avoid an aversive US (e.g. footshock) by remaining in the well-lit side of
a two-chamber apparatus, refraining from entering the dark side where it previously
received the US. Because rodents are nocturnal and prefer darkness, the animal has to
suppress its innate tendency to enter the dark side by forming a learned association
between the dark side and US. Animals that form such an association will cross over
much later (have longer entrance latencies) than animals that remember poorly.
One important difference between Pavlovian fear conditioning and instrumental
fear conditioning is the extent of amygdala involvement. For example, lesions or
pharmacologic inactivation of the BLA impair IA whereas disrupting CeA function does
not[44, 45] [As mentioned, the CeA is required for both contextual and auditory
Pavlovian conditioning][24]. In addition, the amygdala plays a direct role in
consolidating Pavlovian fear memory, in contrast to operant conditioning where
amygdalar influence is brief and less well defined. Furthermore, the number brain regions
impacting IA exceeds those implicated in fear conditioning[44] (see below).
To date, most inactivation and lesion studies have interfered with IA
consolidation, so this phase of mnemonic processing will be emphasized in the discussion
that follows. In short, lesions and reversible inactivation by GABA receptor activation or
sodium channel inactivation have demonstrated IA consolidation occurs over several
hours and involves a multitude of brain regions in a coordinated and sequential fashion.
For example, functional integrity of the hippocampus, BLA, nucleus of the solitary tract
(NTS), and striatum is required during early memory consolidation (initially and up to
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1.5 hours after training), whereas the integrity of brain regions including the nucleus
basalis (NBM), substantia nigra (SN), and parabrachial nucleus (PBNC)—is required for
several hours to days after training[44]. Remarkably, the entorhinal and parietal cortices
are required for at least 1-2 months after acquisition[46]. Notably, the speed of
consolidation (how long each region is necessary) depends on stimulus intensity, number
of training trials and number of shocks administered[44]. The role of the hippocampus,
amygdala and striatum in IA are discussed in detail below.
The dorsal and ventral hippocampus (DH & VH) plays a role in the initial phase
of IA consolidation. Dorsal hippocampus integrity is required for 1.5 h post-conditioning
while ventral activation is needed for 15 min[47, 48]. Functional differences between
these two structures may account for different temporal requirements [Distinct roles for
the DH & VH are also found in spatial navigation[49] (1.3.4)]. Likewise, the amygdala,
particularly the BLA, is required for IA consolidation 0-1.5 h post-training. Infusion of
lidocaine or tetrodotoxin (TTX) into the BLA, for example, reduces IA retention 1.5 but
not 6 h after acquisition[50, 51]. Notably, functional inactivation of CeA does not impair
consolidation of IA[51].
Several structures of the corpus striatum play a critical role in IA acquisition and
consolidation. For example, permanent lesions of the caudate-putamen (CU)[52-54],
nucleus accumbens (NAcc)[52, 55] and globus pallidus (GP)[56] impair the acquisition
of IA. Likewise, TTX blockade of these regions 0.25-1.5 h post-training results in
subsequent IA impairment[52]. Interestingly, functional inactivation of the substantia
nigra (SN) impairs IA consolidation for a longer time period, up to 24 h postconditioning[44].
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1.3.4 Spatial Navigation
`The Morris water maze (MWM) is the most commonly used task for assessing
hippocampus-dependent spatial memory in rodents. It consists of placing a rodent in a
pool filled with opaque water. To escape the pool, the animal learns to swim to a hidden
platform located just below the surface of the water. Over several training trials the
rodent learns to find the platform by using visual and spatial cues, including those
strategically located on the walls outside of the maze. Distance swam, latency to reach
the platform, time spent in each quadrant, number of platform crossings and swim speed
are common measurements of this test.
Lesions and functional inactivation studies have implicated the necessity of
several brain structures in various aspects of MWM learning or performance[57].
Notably, lesions of the amygdala do not impair water maze learning, but influence the
degree of impairment exhibited when other brain regions are concurrently ablated or
transiently inactivated[58-60]. It is well established that functional integrity of the
hippocampus (particularly the DH) is critical for the acquisition, consolidation and
retrieval of spatial information, as supported by temporary inactivation and neurotoxin
lesion studies[61, 62]. Notably, the extent of memory impairment displayed by
hippocampus-lesioned animals is directly proportional the volume of damaged tissue. DH
lesions larger than 20% of the total hippocampal volume dramatically reduce spatial
reference memory. In contrast, lesions of the VH do not significantly impair spatial
navigation[49, 63]. In addition, lesion and inactivation experiments have implicated the
striatum, basal forebrain, cerebellum and neocortex in different aspects of MWM
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learning and sensorimotor function[57]. However, distinguishing between mnemonic and
non-mnemonic contributions from these regions has been extremely difficult. A
consensus is emerging that spatial learning in general and MWM performance in
particular appear to depend upon the coordinated action of many brain regions and
neurotransmitter systems constituting a functionally integrated neural network[57]. Table
1.1 summarizes brain regions involved in each of the paradigms described:
Cued Fear
BLA
CeA
PAG*

Contextual Fear
BLA
CeA
PAG*
DH
VH
NAcc
mPFC

IA
BLA
DH
VH
NTS
NBM
PBNC
SN
Striatum

MWM
DH
Striatum*
Basal Forebrain*
Cerebellum*
Cortex*

Cortex
Table 1.1 Brain Structures Involved
* Involved in Memory and/or Motor Function

in

Specific

Tests

of

Aversive

Memory

1.4 Role of NE/E &-adrenergic signaling in Fear Memory
1.4.1 Epinephrine & Enhanced Consolidation
The adrenergic catecholamine epinephrine (E) is released into the blood from the
adrenal medulla following arousing or stressful situations. Systemic injection of E
immediately after training produces dose-dependent effects on memory consolidation in
rodents: Moderate doses enhance retention, whereas higher doses impair retention (e.g.
an inverted U-shaped dose-response)[64, 65]. In addition, E increases consolidation for
emotionally arousing material in human subjects[66]. Several theories attempt to explain
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E-mediated effects on cognition. For example, evidence suggests that E can stimulate
receptors in the liver to release glucose, and increased glucose levels can enhance
memory consolidation in rats, mice and humans[64]. Furthermore, blocking associated
rises in blood glucose levels prevent E-mediated enhancement of consolidation[67, 68].
Hence, glycogenolysis may play a role in mediating epinephrine influences on memory.
It is also known that E crosses the blood-brain barrier very poorly[69], and E’s effects on
consolidation may be due, in part, to the activation of peripheral β-adrenergic receptors
(e.g. β receptors) on vagal afferents leading to the brainstem[11, 64, 70, 71]. Although
there is limited data that β receptors are located on the vagus nerve, indirect evidence for
this assertion comes from the finding that systemic administration of hydrophobic β
blockers prevents the memory-enhancing effects of E[72]. In addition, E-mediated
activation of the vagus nerve may increase NE centrally by stimulation of brainstem
noradrenergic cell groups in the nucleus of the solitary tract (NTS) and locus coeruleus
(LC)[11, 73]. It is hypothesized that increased synthesis and release of NE in the CNS
leads to the activation of β receptors within the BLA and other brain regions, and that
stimulation of receptors within these structures is what leads to enhanced
consolidation[11, 73]. Support for this comes from the observation infusion of β receptor
antagonists into the BLA prevent enhancement of consolidation by systemically
administered E[74].

1.4.2 Norepinephrine & Enhanced Consolidation
In the CNS, NE/E (adrenergic) neurons are located in 7 brainstem nuclei. The
largest, the LC, provides NE input to most of the forebrain, including the amygdala and
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hippocampus[75]. The adrenergic system is activated by unanticipated or emotional
events[76], and multiple experimental outcomes demonstrate that moderate activation of
this system can enhance the consolidation of fear memory[10, 77]. For example, infusing
NE directly into BLA, NTS or hippocampus before or immediately after training
promotes memory consolidation[11, 73, 78]. However, few studies demonstrate that
adrenergic signaling is actually required for the consolidation of fear memory[79-81].

1.4.3 NE/E is not Required for Fear Memory Consolidation
Pharmacologic and surgical approaches used to reduce or eliminate adrenergic
signaling to study memory have been traditionally limited by two factors: their efficacy
and/or their selectivity for NE/E. NE/E synthesis inhibitors, for example, either impair
dopamine

(DA)

signaling

(e.g.

-methyl-p-tyrosine,

a

tyrosine

hydroxylase

inhibitor)(Figure 1.1) and/or inhibit other Cu2+/Zn2+-dependent enzymes in addition to
dopamine -hydroxylase (DBH)[82-84]. Similarly, electrolytic and neurotoxic lesions of
brainstem adrenergic neurons or their projections are incomplete, nonspecific or transient
because of recovery mechanisms that occur in the remaining adrenergic neurons and
terminals[85-89]. To circumvent these issues, mice with a targeted disruption of the gene
for DBH (Dbh) were created (Figure 1.1). Knocking out this enzyme results in mutant
(Dbh-/-) mice, which lack the capacity to produce both NE and E[90, 91]. Multiple
experimental outcomes from these animals demonstrate that NE/E is not required for the
consolidation of fear memories. For example, Dbh-/- mice, compared to controls, exhibit
equivalent short and long-term retention of IA and cued fear[92, 93]. Further, deficits
exhibited by NE-deficient mice in contextual and spatial memory fully dissipate 5 or
12

more days after training[92]. Hence, consolidation processes have occurred in the
absence of NE/E, leaving long-term fear memory intact.

Figure 1.1 Catecholamine Biosynthesis Pathway

1.4.4  Signaling is not Required for Fear Memory Consolidation
Analogous to increasing endogenous NE in the BLA by microinfusion, directly
stimulating -adrenergic receptors in the BLA enhances fear memory consolidation[73].
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Despite studies demonstrating that enhanced signaling can promote memory
consolidation, there is a paucity of evidence showing that  signaling is required for fear
memory consolidation. In fact, multiple experimental outcomes demonstrate the contrary,
summarized as follows: 1) WT mice and rats treated with a non-selective  antagonist
before or immediately after training exhibit normal contextual and spatial reference
memory 5 days later[92]; 2) 1KO and 2KO mice express no deficit in IA (Chapter 2);
3) 1KO, 2KO and 12 DKO animals display no deficit in cued fear[92]; (Chapters 2,4)
1KO and 2KO mice express unimpaired contextual fear 5 or more days after
training[92](Chapter 4); and 5) 12 DKO mice display unimpaired long-term memory of
contextual fear, similar to their WT counterparts (Chapter 2). In sum, these results are
inconsistent with a requirement for  signaling in fear memory consolidation.

1.4.5 NE/E is Required for Intermediate-term Memory Retrieval
1.4.5.1 NE/E and Spatial Retrieval
Dbh-/- mice exhibit impaired spatial reference memory 2 d (but not 2 h) after the
last training trial, initially suggesting that NE/E is necessary for consolidation rather than
the acquisition of this task[92]. Complicating interpretation of spatial navigation results is
the extended training that is usually necessary for mice to acquire the task. Acquisition,
consolidation, retrieval and reconsolidation occur repeatedly during such training, so it
becomes difficult to assign deficits to a single stage of learning.

1.4.5.2 NE/E and Contextual Memory Retrieval
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A major advantage of examining contextual fear, in addition to spatial navigation,
is that robust acquisition can occur in a single trial, and this allows examination of
acquisition, consolidation or retrieval in isolation by manipulating any single stage of
learning at a particular time. Interestingly, contextual memory retrieval was impaired
from two hours to several days after training, which was initially consistent with a
possible role for NE in hippocampus-dependent memory consolidation, but a more
thorough analysis revealed that this was not the case.
An important component of the Dbh-/- model is the ability to rapidly restore NE in
the mutant mice either before or after training (or prior to testing) by administering a
synthetic amino acid precursor of NE, L-threo-3,4-dihydroxyphenylserine (L-DOPS,
Figure 1.1)[90]. L-DOPS restores NE tissue content to near normal levels for ~12 h, with
NE levels peaking approximately 5 h after injection[90]. Remarkably, restoring NE
before or immediately after training did not rescue memory consolidation because 2 days
after L-DOPS administration, Dbh-/- mice continued to express deficits in contextual fear.
In contrast, administering L-DOPS before testing 1 or 2 days after training fully reversed
deficits exhibited by these animals[92]. In addition, Dbh-/- mice exhibited normal
contextual memory 5 d after training without any treatment, arguing against a
requirement for NE in fear memory consolidation[92]. In sum, experimental outcomes
from both paradigms demonstrate a critical, transient role for NE in the retrieval of fear
memory.

1.4.6  Signaling is Required for Intermediate-term Memory Retrieval
1.4.6.1  Signaling and Spatial Retrieval
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Many studies exploring the role of NE and -adrenergic signaling in fear memory
have utilized rats, so experiments were conducted to test whether spatial navigation
deficits displayed in NE/E-deficient mice also applied to rats whose adrenergic signaling
was disrupted by administration of a non-selective  antagonist. [Using rats in the water
maze possessed an added advantage because rats, unlike mice, can acquire this task
rapidly (e.g. 4 blocks of 4 trials over 90 min)[94], so specific stages of learning can be
better manipulated and dissected]. Systemic injection of the  antagonist, propranolol,
produced no effect on spatial reference memory in rats when given shortly before
training, or shortly before testing 1 h or 1 wk after training[92]. However, rats exhibited
reduced spatial bias 1 d after training, when the  antagonist was administered shortly
before testing, providing evidence that -adrenergic signaling is required for
intermediate-term retrieval of spatial reference memory across species[92].
1.4.6.2  Signaling and Contextual Memory Retrieval
Administration of propranolol or either of several 1-adrenergic receptor
antagonists to control mice before testing contextual fear reproduces retrieval deficits
expressed by Dbh-/- mice[92]. In addition, treating Dbh-/- mice with a 1 agonist just
before testing completely reverses contextual freezing impairments[92]. These
observations also hold true in rats, as 1 antagonists yield similar results[92].
Interestingly, these findings suggest that 1-signaling is both necessary and sufficient for
hippocampus-dependent memory retrieval mediated by NE. However, it does not exclude
the possibility that constitutive signaling by other adrenergic receptors in the absence of
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NE can influence retrieval (Chapter 2), nor does it exclude the possibility that other
adrenergic receptors can signal in similar or opposing ways to produce affects on
retrieval in addition to 1 signaling (Chapters 2, 4).
1.4.6.3  & Receptors Influence Retrieval Independent & in Concert with 
Chapters 2-4 provide support that NE/E exerts some effects on the retrieval of
hippocampus-dependent fear memory by activating other  receptors, alone or in
conjunction with 1. In general,  receptors can be classified into 3 subtypes based on
pharmacologic specificity and the intracellular signaling pathways they modulate[95]
(Table 2.1). IHC, ISH and radioligand binding studies have demonstrated that  receptors
have overlapping, but somewhat unique expression patterns throughout the CNS[96-100].

Subtype
Agonists
Antagonists
G protein
Effectors

1
Xamoterol
Betaxolol, CGP
Gs
Adenylyl Cyclase
cAMP


Procaterol, Zinterol
ICI 118551
Gs, Gi/o
Adenylyl Cyclase
cAMP


CL 316243
SR 59230A
Gs, Gi/o
Adenylyl Cyclase
cAMP

Table 1.2 -adrenergic Receptors, their Pharmacology and Signaling

1.5 Role of Stress & Glucocorticoids in Fear Memory
1.5.1 Stress, Glucocorticoids (GCs) & Consolidation
GCs are stress hormones released from the adrenal cortex that penetrate the
blood-brain barrier and bind to two types of adrenal steroid receptors, glucocorticoid
receptors (GRs) and mineralocorticoid receptors (MRs), the latter of which have higher
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affinity for glucocorticoids[101]. Under stressful circumstances, increases in circulating
GCs cause low-affinity GRs to become increasingly saturated, and it is these receptors
that are believed to be primarily involved in mediating GCs effects on memory [59, 102107], although some studies suggest a role for MR as well[108]. Like NE and  signaling,
stress and GCs have been shown to enhance long-term memory consolidation in both
humans and animals when administered shortly before or after training [109-112].
Moreover, CNS infusion of GR agonists and antagonists in rodents produce divergent
effects on consolidation. For instance, systemic injection or direct infusion of GCs (or
GR agonists) into the NTS, BLA or hippocampus augments consolidation while
administration of GR antagonists impairs consolidation[59, 103, 113-115]. Traditionally,
it was believed that GCs influence consolidation by binding to intracellular and
intranuclear receptors which affect gene transcription by binding of receptor homodimers
to DNA or via protein-protein interactions with other transcription factors[116-118].
Alternatively, it been demonstrated that GCs can interact with membrane-associated
steroid receptors[119-121] and these receptors may influence consolidation by rapidly
altering cAMP-PKA signaling[11, 122]. For instance, infusion of GCs into the BLA is
believed to facilitate -cAMP-PKA signaling, and infusion enhances the consolidation of
fear memory[11, 122].

1.5.2 Stress, GCs & Retrieval
Stress and GCs have been shown to impair short-term and long-term memory
retrieval in humans and animals[123-125]. For example, administration of stress or GCs
shortly before testing impairs the retrieval of spatial reference memory[123], contextual
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fear (Chapter 2), IA[126] and human declarative memory[127]. Effects of GCs on
retrieval are often transient, waning several hours after stress exposure or hormone
injection[128]. Similarly, experiments in Chapter 2 demonstrate that the influence of
acute stress and GCs on retrieval dissipates several days after acquisition, even if GCs are
administered shortly before testing (Chapter 2). In contrast, prolonged exposure to high
levels of GCs, chronic stress and corresponding HPA dysfunction can cause long-lasting
impairments of declarative/episodic memory[129]. However, these deficits are probably
not retrieval-based, but reflect impaired consolidation processes. As opposed to processes
underlying GC-mediated consolidation, GC processes pertaining to retrieval may be
regulated solely through rapid, non-genomic mechanisms[130, 131].

1.6 Interactions between Adrenergic & GC Signaling in Fear Memory
1.6.1 NE/E,  Receptor & GC Interactions in Consolidation
Blocking the synthesis of E and GCs by removing or suppressing the adrenals
both cause deficits in fear memory consolidation[132, 133]. Also, the consolidation
effects of E are critically influenced by GCs. For example, the memory-enhancing effects
of E (or stress) are blocked by metyrapone, a drug that prevents the synthesis and release
of glucocorticoids[132, 134]. Glucocorticoid-based effects on consolidation likely
involve concurrent noradrenergic activation within the BLA[128]. For example,
propranolol-mediated block of β-adrenoceptors within the BLA prevents the memoryenhancing effects of systemic or intra-NTS GC administration[115, 135]. Similarly,
infusions of receptor antagonist into the BLA shortly before IA training blocks the
enhancement of memory consolidation brought about by systemic administration of
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dexamethasone, a GR agonist[136]. Likewise, infusion of the antagonist atenolol into
the BLA prevents the memory enhancing effects of a GR agonist infused into the
hippocampus[104]. Moreover, the enhancement in IA consolidation mediated by
stimulation of GRs in the NTS is prevented by infusion of atenolol into the BLA[115].
A common hypothesis is that GCs enhance memory consolidation by increasing
the synthesis and release of NE within the BLA and other brain regions[11, 137]. Some
indirect evidence supports this observation. For example, systemic administration of
corticosterone after IA training increases NE levels in the BLA[138]. GCs have also been
shown to block a specific catecholamine-transporter in glial cells, known to rapidly
remove extracellular NE[139].
1.6.2 NE/E, Receptor & GC Interactions in Retrieval
Co-administration of a antagonist prevents GC-mediated retrieval impairment
of IA[140]. Similarly, infusion of a  antagonist into the hippocampus or BLA mitigates
the impairing effects of concurrent intra-hippocampal administration of GR agonist on
spatial reference memory[141]. Interestingly,  antagonists infused into the BLA also
block the memory retrieval impairing effects of a GR agonist infused into the
hippocampus[141]. Further, it has been reported that DH infusion of a  antagonist
blocks GR-agonist mediated deficits in spatial navigation and that systemic
administration of a partial  agonist, xamoterol, mimics GC-mediated effects on
memory retrieval[141]. However, evidence from our lab suggests that GC effects on
retrieval actually depend on  rather than  signaling (Chapter 2).
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1.7 GCs &  Signaling can Influence cAMP-PKA Signaling
1.7.1 cAMP-PKA & Fear Memory Consolidation
It has been suggested that the consolidation of hippocampus-dependent memory
modulated by NE and GCs involves common neurobiologic substrates and signal
transduction pathways, including cAMP and protein kinase A (PKA) signaling. Three
decades of research across species illustrate that agents that elevate cAMP usually
enhance memory consolidation, whereas agents that block cAMP signaling impair
consolidation[142-146]. In addition, pharmacologic and genetic results in several species
illustrate that cAMP-mediated PKA signaling is necessary for the consolidation of longterm fear memory[3]. For example, transgenic mice expressing a cAMP-insensitive form
of a regulatory subunit of PKA exhibit deficits in spatial and contextual memory[147]. In
addition, ICV or intrahippocampal administration of a PKA inhibitor disrupts IA
consolidation [3, 144, 148, 149]. A major effector of PKA is cAMP response element
binding (CREB) protein and transgenic mice lacking specific isoforms of CREB,
dominant-negative CREB mutants and mice expressing truncated forms of CREBbinding protein (CBP) display impairments in spatial, contextual and auditory fear
memory[3, 150-152].
GCs appear to promote cAMP-PKA signaling in order to enhance memory
consolidation[122]. For example, BLA infusion of the cAMP-dependent PKA inhibitor,
Rp-cAMPS prevents GR agonist-mediated enhancement of IA[122]. However, infusion
of a GR antagonist into the BLA does not prevent the augmentation of memory
consolidation produced by concurrent injections of the cAMP activating analog, 8-Br21

cAMPS[122]. Hence, cAMP-PKA mediated enhancement of consolidation could be
either 1) independent of GC signaling and/or 2) GCs effects occur upstream of cAMP,
perhaps on NE release and/or activation of adrenoceptors[11, 122].

1.7.2 cAMP-PKA & Fear Memory Retrieval
Recent evidence suggests PKA signaling is involved in hippocampus-dependent
memory retrieval. For example, activation of both PKA and exchange protein activated
by cAMP (Epac) is required for CF retrieval[153]. Likewise, infusion of PKA inhibitors
into the DH shortly before testing transiently impairs the retrieval of contextual
information[153]. Further, CA1 infusion of a PKA inhibitor (Rp-cAMPS) impairs
retrieval of IA[154]. Interestingly, restoring PKA-Epac signaling fully reverses
contextual retrieval deficits exhibited by mice lacking NE/E, indicating the PKA-Epac
signaling is necessary and sufficient for NE’s role in hippocampus-dependent
retrieval[153].
It should be noted, however, that cAMP effects on consolidation and/or retrieval
may not always be dependent on PKA signaling. Most of these agents described inhibit
or restore cAMP signaling (e.g. effects are not-specific to PKA) and other targets of
cAMP could possibly contribute (e.g. ion channels).
It has been suggested that GCs facilitate -adrenergic signaling to inhibit
retrieval, but how this occurs is inconclusive. My studies demonstrate that stress and GCs
enhance  signaling in order to impair retrieval, which, in turn, leads to a reduction in
cAMP-PKA signaling that is necessary for hippocampus-dependent recall (Chapter 2).
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1.8 Scope of Thesis Research
The major aim of this thesis work is to examine interactions between stress, GCs,
NE/E and -adrenergic signaling in aversive hippocampus-dependent memory retrieval.
Pharmacological and genetic manipulations of NE and  adrenoceptors were utilized to
access adrenergic contributions to stress- and GC-mediated retrieval impairment in vivo,
using behavioral paradigms specifically designed to test both hippocampus-dependent
(e.g. CF, IA) and –independent (e.g. cued) fear memory. Corticosterone and cAMP
radioimmunoassays were employed that provided molecular analysis of GC, stress and 
receptor effects that correlated well with behavioral results. Systemic and/or
intrahippocampal injections using a wide range of doses produced consistent results
across preparations in both mice and rats. Conclusions justified from the data will
significantly expand scientific knowledge about the complex interplay between  and GC
signaling in retrieval while casting doubt on two prevalent but seldom tested hypotheses
(e.g. that NE and  signaling are required for GC-mediated effects on retrieval). In
addition, initial results begin to define a molecular mechanism for how GCs, GRs, and 2ARs intersect to impair retrieval. Furthermore, evidence is presented that characterizes
novel and potentially important roles for 2 and 3 receptors in aversive learning and
memory, whose functions can be dependent and independent of 1 signaling.

1.9 Clinical Significance of this Work
1.9.1 Adrenergic & GC Therapies in Post-traumatic Stress Disorder (PTSD)

23

One of the cardinal symptoms of PTSD is the excessive retrieval and
reconsolidation of traumatic memories. During the last decade, a growing number of
clinical studies have administered adrenergic and GC-related compounds in attempts to
treat the disease. This section highlights some of this work and attempts to explain why
outcomes have been inconsistent. Furthermore, limitations of adrenergic- and GC- based
therapies in reducing the frequency of traumatic memories are discussed.
1.9.2 -adrenergic Antagonists & Agonists for PTSD
Evidence suggests that -adrenergic antagonists, such as prazosin, may be
beneficial in treating specific symptoms of PTSD, such as nightmares and other
difficulties sleeping[155-157]. In addition, clonidine, an -adrenergic agonist, has been
shown to be effective in reducing symptoms of hyperarousal and startle associated with
the disease[158]. However, these compounds are largely ineffective in treating most other
symptoms of PTSD, such as the recurrent, intrusive retrieval of traumatic memories.
1.9.3 -adrenergic Antagonists & Agonists for PTSD
1.9.3.1 Reducing Consolidation
Horrific events often leave indelible marks in human consciousness, permanent
scars that may never heal. Heightened arousal and release of stress hormones after such
harrowing experiences can result in over-consolidated memories which are highly
resistant to degradation. Further, cues reminiscent of the trauma are believed to increase
the release of stress hormones which cause further over-consolidation, promoting a
vicious cycle that contributes to the development/expression of PTSD[159]. In rodents,
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-adrenergic blockade immediately after aversive experiences reduces the enhancement
of consolidation caused by stress (1.6.1). Based on this finding, studies were conducted in
humans to investigate whether  blockers (e.g. propranolol) might assist in the secondary
prevention of PTSD by interfering with consolidation processes believed to occur hours
to days after the event. Initial studies supported this hypothesis, as individuals treated
with propranolol 0-4 h after a motor vehicle accident show reduced PTSD symptoms
weeks to months after the event[160]. Likewise, adults who recently experienced one of
two forms of trauma (e.g. a motor vehicle accident or physical abuse) also found longlasting benefit of propranolol administration 2-20 h after the trauma[161]. Notably,
propranolol was continually administered for several days after initial dosing, so
improvements due to receptor blockade cannot be firmly attributed to interfering with
consolidation.
Interestingly, recent studies consistently fail to show a benefit for propranolol
soon after experiencing any one of several forms of trauma (e.g. burns, severe
injury)[162-164]. These results agree with rodent data produced by our lab and others
demonstrating that  blockade does not impair the consolidation (e.g. ―strength‖) of fear
memories per se[165] (also see 1.4.4). For example, consolidation of cued fear is
unaffected by propranolol or NE/E deficiency and cues associated with the trauma often
trigger the strongest recall for the event.

1.9.3.2 Reducing Retrieval
Interestingly, propranolol impairs the retrieval of hippocampus-dependent fear
memory in rodents[92]. Conversely, evidence from humans demonstrates that
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administration of propranolol shortly before testing improves SAT exam performance in
anxiety-ridden students and increases cognitive flexibility and problem-solving ability in
nervous examinees[166-168]. It should be noted that in the animal study, propranolol is
administered before re-exposure to a stressful environment, while in the human study,
propranolol is administered to subjects that are already stressed. It is theorized that
receptors become increasingly activated during stress, and propranolol-mediated
blockade of -ARs could prevent stress-induced impairment of retrieval, similar to
effects of antagonists in rodents (Chapter 2). In contrast, propranolol has been
demonstrated to block  signaling that is necessary for retrieval[92]. One explanation for
conflicting results is that  signaling can oppose the role of  signaling in retrieval
(Chapter 2), so utilizing a non-selective  antagonist might lead to inconsistent results.
Instead, administration of a selective 1 antagonist or 2 agonist might be more
efficacious in reducing PTSD memories, given knowledge about the molecular
mechanisms underlying the retrieval of hippocampus-based fear memory[92] (Chapter 2).
However, this too might be unproductive as our lab has demonstrated that propranolol’s
effectiveness in reducing retrieval is limited by the age of the memory[92]. Similarly, the
utility of  antagonists might wane over time because hippocampus-dependent retrieval
becomes independent of adrenergic signaling[92].

1.9.3.3 Reducing Reconsolidation
Instead, the utility of propranolol for PTSD might be in interfering with
mnemonic processes that occur following retrieval, such as reducing the reconsolidation
of fear memories (or promoting

extinction) [169]. Initial evidence suggests that
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medicating patients with  blockers for short stretches when symptoms are already
prevalent (or after reexposure therapy) might be beneficial because memories may
become labile again, i.e. they may be strengthened or weakened. Animal studies support
this hypothesis. For example, systemic or BLA blockade of  receptors following
reactivation of fear memory disrupts reconsolidation and impairs long-term auditory fear
memory in rats[165, 170]. Moreover, administration of systemic propranolol following
reactivation produces long-term impairment of IA[171]. Interestingly, such studies
suggest that propranolol can impair the reconsolidation of both hippocampus-dependent
and -independent fear memories; translationally, this might lead to better efficacy, given
that PTSD populations are heterogeneous. Notably, -adrenergic blockade following
retrieval in humans reduces memory of emotionally enriched words (declarative memory)
for at least several days after administration[172]. In contrast, others have shown less
benefit for propranolol in inhibiting the reconsolidation of traumatic memories. For
example, a recent study in rodents demonstrates that propranolol may only block the
reconsolidation of specific types of fear memory[173]. Moreover, administration of
propranolol after reactivation of conditioned fear in humans produces a long-lasting
reduction in the fear response but not in declarative memory for the fear association
itself[174]. Thus, the utility of propranolol to inhibit reconsolidation of traumatic
memories has yet to be determined.

1.9.4 Glucocorticoids for PTSD
1.9.4.1 Reducing Consolidation
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Like  blockers, administering GCs soon after a traumatic experience may reduce
the onset or severity of PTSD by blocking the consolidation of fear memories. For
example, individuals receiving high doses of GCs after major surgery or septic shock
display reduced recall of events associated with the trauma[175-177]. Notably,
hydrocortisone administration was continued for several days after initial dosing, so
improvements cannot fully be attributed to affecting any single stage of memory (e.g.
consolidation). Benefits of GCs in PTSD patients is at odds with the well-replicated
finding that GCs enhance the consolidation of fear memories in both animals and
humans(see 1.5.1). One alternative explanation is that endogenous levels of GCs are
lower in patients that develop PTSD[178, 179], and increasing cortisol after a horrific
experience may restore signaling to normal levels. It is hypothesized that restoring
cortisol function attenuates the exaggerated stress response (e.g. through negative
feedback inhibition) in individuals who are prone to develop the disorder[180, 181].

1.9.4.2 Longer-term GC Administration can Impair Memories Unrelated to the
Trauma
Long-term exposure to high levels of GCs can produce cognitive deficits in
episodic memory that can impair everyday functioning[182] and may create impairments
more debilitating than the disease itself. In fact, evidence suggests that long-term GC
exposure or stress may cause permanent hippocampal damage via cumulative and longlasting changes in synapse function and morphology which negatively affect declarative
memory[183-185]. In addition, chronically elevated GC levels that are associated with
either long-term treatment or HPA dysfunction can exacerbate existing psychiatric
illnesses and increase the risk for major depression and psychosis[186].
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1.9.4.3 Reducing Retrieval by Long-term, Low-dose GC Administration
Clinical studies have attempted to circumvent adverse affects of chronic, highdose GC administration by employing low doses of GCs to treat PTSD patients over
extended times [12, 188] (such doses have not been shown to create cognitive deficits).
Interestingly, evidence from our lab and others support initial clinical evidence that low
doses might be more efficacious in inhibiting the retrieval of unwanted memories[12,
188](Chapter 2). However, initial studies that chronically administer GCs have had
limited success, only reducing select symptoms of the disease that vary between
individuals (e.g. nightmares, hyperarousal, feelings of re-experiencing the event)[187].
Moreover, a significant treatment effect in reducing the retrieval of traumatic memories
has not been reported. The latter result is consistent with findings by our lab
demonstrating that GCs impair the retrieval of fear memories for a limited time in
rodents(Chapter 2), so long-term clinical administration might be ineffective, because
retrieval processes may, over time, become insensitive to GC manipulation.

1.9.4.4 Reducing Reconsolidation
Utilizing GCs to interfere with reconsolidation processes (or promote extinction)
may be more beneficial that utilizing GCs to interfere with consolidation or retrieval. In
theory, administering GCs during or immediately after reexposure (or after recreating the
trauma) may weaken the memory trace and thus reduce PTSD symptoms beyond the
treatment period. Preliminary studies in animals and humans suggest this might hold true.
In rodents, administration of a GC after memory reactivation disrupts subsequent recall
of context fear 2 weeks later [188, 189]. Similarly, combat veterans shown images
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reminiscent of wartime trauma immediately preceding GC administration showed
reduced PTSD symptoms 1 wk later[190]. However, benefits of GCs following
reactivation may wane over time (similar to affects on retrieval), as veterans showed little
benefit when tested 1 month later[190].
Paradoxically, administration of GR antagonists into the BLA after retrieval also
cause impairments in IA and cued fear that persist for at least several days[191, 192]. At
first pass, it seems logical that blockade of GR signaling impairs reconsolidation, because
GR signaling is required for consolidation of fear memory. It is possible that deficits
mediated by GCs and GR antagonists are the result of opposing effects on
reconsolidation and extinction[169, 193], similar to opposing functions demonstrated in
the consolidation and retrieval of aversive memories. In other words, GCs may promote
extinction (or promote the consolidation of corrective responses) while GR antagonists
may inhibit the over-consolidation of fear memories believed to occur after re-exposure
to the trauma.

1.10 Statement of Purpose
A major goal of this thesis was to resolve the conflicting observations that NE and 1
signaling are required for contextual and spatial memory retrieval (in mice and rats) but
also necessary for stress and glucocorticoid impairment of hippocampus-dependent
emotional memory[92, 141]. Because GC deficits are completely blocked by a nonselective  antagonist[141], we examined whether another adrenergic receptor (2) was
responsible for stress/GC inhibition of episodic memory (Chapter 2). A second goal was
to confirm the validity of a study suggesting that 1 and 2 are both required for the
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consolidation of fear memory[194]. Our results are consistent with most studies that have
failed to demonstrate a requirement for either receptor in the consolidation of Pavlovian
fear conditioning (e.g. propranolol does not impair auditory fear; cued fear and IA are
normal in 1KO, 2KO, 12 DKO mice)[92, 165](Chapter 2). A third aim was to refute a
common notion that all CNS  receptors function in a similar ways in aversive learning
and memory. For example, it was reported that GC enhancement of consolidation can be
prevented by either 1 or 2 blockade, suggesting a redundant role for these receptors in
auditory fear learning[136]. In contrast, experiments presented in the chapters that follow
demonstrate that  receptors play highly different roles in retrieval, which parallels
mounting evidence for distinct roles for the two receptors in stages of fear memory such
as consolidation (communications with M. Ouyang & S.A. Thomas). A final goal of this
work was to demonstrate that divergent roles of receptors can be mediated through
opposing effects on intracellular signaling pathways, such as cAMP.
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Chapter 2

Stress and Glucocorticoids Impair
Hippocampus-dependent Emotional
Memory Retrieval via Gi/o-coupled2adrenergic Signaling
Keith Schutsky, Ming Ouyang, Christina B. Castelino, Lei
Zhang & Steven A. Thomas

Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104

Author contributions: K.S. and S.A.T. designed research; K.S., M.O., C.C., L.Z and
S.A.T. performed research; K.S., M.O., C.C. and S.A.T. analyzed data; K.S. and S.A.T.
wrote the paper.
32

2.1 ABSTRACT
Stress and glucocorticoids impair the retrieval of hippocampus-dependent
emotional memory. It has been proposed that glucocorticoids act by promoting the
release of norepinephrine (NE), which impairs retrieval by stimulating 1-adrenergic
receptors and cAMP signaling. In contrast, evidence indicates that NE, 1 and cAMP
signaling are transiently required for the retrieval of hippocampus-dependent emotional
memory. Here we report that glucocorticoids do not require NE to impair retrieval.
Despite this, stress- and glucocorticoid-induced impairment of retrieval depends on the
activation of 2-adrenergic receptors (not 1).

Importantly, the effects of stress,

glucocorticoids and 2 agonists are blocked by pertussis toxin, suggesting that they act
through Gi/o proteins. In support of this, 2 signaling in isolation decreases cAMP in the
hippocampus, and when combined with 1 signaling, prevents the increase in cAMP
elicited by 1 receptors. The results demonstrate that 1 and 2 receptors can have quite
distinct roles in CNS signaling and in cognition.

2.2 INTRODUCTION
Stress and glucocorticoid hormones (corticosterone in animals, cortisol in
humans) can have pronounced effects on cognition[127, 195, 196]. Glucocorticoids
activate mineralocorticoid (MR) and glucocorticoid (GR) receptors, both of which are
prevalent in the hippocampus[101, 197].

Glucocorticoids preferentially occupy MR

under basal physiologic conditions; however, glucocorticoid levels rise significantly
following a stressor, causing substantial additional activation of GR[101]. The impact of
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glucocorticoids on mnemonic processes can vary considerably, depending upon when
and to what extent levels of these hormones are altered and the specific stages of learning
that are examined. When administered shortly after training, glucocorticoids enhance the
consolidation of hippocampus-dependent emotional memory[103, 110], and a GR
antagonist administered shortly after training impairs hippocampus-dependent emotional
memory consolidation[102, 103, 198].
Conversely, administration of stress or glucocorticoids shortly before retention
testing impairs the retrieval of hippocampus-dependent emotional memory in animals and
humans[123, 124, 199]. Infusion of the GR-selective agonist RU 28362 into the dorsal
hippocampus (DH) 60 min before retention testing impairs retrieval[107], and viral
expression of a transdominant GR in the dentate gyrus prevents retrieval impairment by
corticosterone (cort)[106], strongly suggesting that retrieval impairment is mediated by
GR. However, a role for MR is also possible. Intracerebroventricular administration of
the MR antagonist spironolactone is reported to mitigate cort-induced impairment of
spatial reference memory[108].
Accumulating evidence suggests that glucocorticoids and other steroid hormones
can operate through non-genomic as well as genomic mechanisms[200, 201]. Generally,
genomic mechanisms affect protein expression occurring over tens of minutes to hours.
In contrast, non-genomic mechanisms are much more rapid, occurring within seconds to
minutes.

Cort likely affects memory retrieval through non-genomic, membrane-

delimited mechanisms. Intracerebroventricular administration of anisomycin, a protein
synthesis inhibitor, does not alter cort-induced impairment of spatial navigation in
rats[131], and DH infusion of protein-conjugated cort, which selectively activates
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membrane-associated receptors[202, 203], mimics the effects of stress on serial memory
retrieval[204].
Offering a potentially rapid, non-genomic mechanism for glucocorticoid action,
results from some studies suggest that both the impairment of retrieval and the
enhancement of consolidation by cort depend on signaling by the adrenergic
neurotransmitters norepinephrine and epinephrine (NE/E). -adrenergic signaling, in
particular, may be critical.

Administration of the  receptor antagonist propranolol

prevents glucocorticoid-induced impairment of retrieval in rats and humans[140, 141,
205]. Further, DH infusion of the 1-selective receptor antagonist atenolol blocks the
impairing effects of the GR agonist RU 28362 in the Morris water maze, and systemic
administration of the 1-selective agonist xamoterol mimics the effects of RU
28362[141].
The suggestion that 1 signaling is responsible for the impairing effects of
glucocorticoids on retrieval is at odds with the recently described requirement for 1
signaling in hippocampus-dependent emotional memory retrieval. Targeted disruption of
the dopamine -hydroxylase gene (Dbh-/-) in mice results in NE/E deficiency and deficits
in the Morris water maze and contextual fear conditioning that reflect impaired memory
retrieval[92, 93]. Administration of the 1-selective agonist xamoterol shortly before
testing rescues retrieval in Dbh-/- mice, suggesting that 1 signaling is sufficient for the
role of NE/E in retrieval[92]. In support of this, mice with targeted disruption of the gene
for the 1 receptor (1 KO) display deficits in contextual fear memory, and systemic
administration of the 1-selective antagonist betaxolol produces similar retrieval deficits
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in wild-type mice and rats[92]. Finally, these effects are mimicked by infusion of the 1selective antagonist atenolol into the DH.
The goal of this study, then, was to resolve the seemingly conflicting observations
that 1 signaling is both required for hippocampus-dependent emotional memory retrieval
and responsible for the impairment of such retrieval by glucocorticoids.

We

hypothesized that the pharmacologic characterization of the glucocorticoid-induced
retrieval impairment is incomplete, and that another adrenergic receptor may mediate this
effect. We further hypothesized that the intracellular signaling activated by this receptor
may oppose the intracellular signaling activated by 1 receptors. Toward this goal,
animals were tested in both Pavlovian and instrumental fear conditioning paradigms.
Pharmacologic reagents previously untested in these paradigms were administered to
wild-type rats and mice, as well as to mice genetically modified to lack either NE/E, 1or 2-adrenergic receptors.

Because glucocorticoids are thought to underlie the

impairment of hippocampus-dependent memory retrieval by stress, additional
experiments examined the effects of stress on retrieval. The results provide substantial
and unexpected support for the idea that signaling by 2-adrenergic receptors in the
hippocampus opposes signaling mediated by 1 receptors at both the molecular and
behavioral levels. This finding is inconsistent with the classic view that both  receptors
couple to Gs proteins and elevate levels of cAMP, but is consistent with the divergent
signaling mechanisms and roles for these two receptors in the heart[206, 207].
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2.3 RESULTS
2.3.1 Corticosterone and a GR Agonist Impair Hippocampus-dependent Memory
Retrieval
Most previous animal studies examined the impact of stress or glucocorticoids on
the retrieval of instrumental fear memory (inhibitory avoidance) or spatial reference
memory (Morris water maze). For comparison to previous studies, inhibitory avoidance
was used in the current study. In addition, we asked whether the retrieval of Pavlovian
contextual fear memory, like spatial reference memory, would be sensitive to
glucocorticoids. Potential advantages of studying contextual fear memory include its
robustness, rapid acquisition, and the use of dorsal hippocampus-independent cued fear
memory as a control for potential effects on performance.
When cort was administered subcutaneously 30 min prior to testing retrieval one
day after training, mice had lower avoidance latencies and reduced contextual freezing in
these two paradigms (Figures 2.1A and 2.1B).

In both, deficits produced by cort

followed a U-shaped dose-response over a 10-fold dose range, with 1 mg/kg cort
producing maximum impairment. To test whether cort might act through a GR-like
mechanism, the selective GR agonist fluticasone was administered before testing
contextual fear[208]. Like cort, fluticasone impaired contextual freezing in a U-shaped
manner (Figure 2.1C).
To corroborate the finding that glucocorticoids act in the hippocampus to impair
retrieval, bilateral cannulae targeting the DH were implanted and mice were fear
conditioned one week later. One day after training, either vehicle or cort was infused
bilaterally into the DH 15 min before testing. There was a dose-dependent decrease in
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contextual freezing that, at 50 ng, was similar to the magnitude observed after systemic
treatment (Figure 2.1D). Unlike systemic treatment, however, the effect of cort over a
10-fold dose range in the DH was not U-shaped, with 100 ng producing a similar effect to
that for 50 ng. In support of a non-genomic mechanism of action, DH infusion of 20 ng
cort 7.5 min prior to testing contextual fear produced the same degree of impairment as
20 ng infused 15 min prior to testing (Figure 2.1E).
Finally, to determine whether glucocorticoid impairment of contextual fear was
specific to hippocampus-dependent memory retrieval, cort was administered prior to
testing cued fear. Neither systemic nor DH cort impaired cued fear expression, indicating
that these treatments do not alter fear, freezing or hippocampus-independent memory
retrieval (Figure 2.1F).
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P < 0.01, # P < 0.001 for post-hoc comparisons. (C) Fluticasone, a GR agonist, mimics the

39

impairment of CF by cort. P < 0.001 for the main effect of dose (5-6/group). (D) Infusion of
cort into the dorsal hippocampus (DH) impairs CF. P < 0.001 for the main effect of dose (56/group). For all figures, DH infusions occurred 15 min prior to testing one day after training
unless stated otherwise. (E) Cort impairment of CF is rapid, suggesting a non-genomic
mechanism. Cort was infused 7.5 min prior to testing one day after training (5/group). (F)
Neither subcutaneous (SC) injection nor DH infusion of cort affects cued fear (5-8/group).

2.3.2 Impairment of Retrieval by Glucocorticoids Depends on 2 Signaling but not
NE/E
Several studies have suggested that glucocorticoid-induced impairment of
memory retrieval may depend upon the release of NE in the CNS[115, 140, 141]. To test
this idea, wild-type and NE/E-deficient Dbh-/- mice were administered cort systemically
30 min prior to testing retrieval one day after training. Instrumental fear conditioning
was used because, unlike the retrieval of contextual fear that depends on NE/E, the
retrieval of instrumental fear is normal in Dbh-/- mice[93]. Importantly, the degree of
cort-induced impairment displayed in Dbh-/- mice was similar to that seen in control
mice, indicating that NE/E are not required for the impairing effects of glucocorticoids on
retrieval (Figure 2.2A).
Previous results using the 1-selective antagonist atenolol and the 1-selective
agonist xamoterol suggest that disruption of memory retrieval by glucocorticoids depends
on 1 signaling[141]. Those findings are in direct contrast to observations indicating that
1 signaling is necessary for the retrieval of an intermediate phase of contextual and
spatial memory[92]. One possible resolution for this discrepancy is that atenolol and
xamoterol affect receptors in addition to 1 at higher doses, and that this other receptor is
responsible for the effects of these drugs on retrieval. A likely candidate for this receptor
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is the 2-adrenergic receptor, which is closely related to the 1 receptor and is also
relatively abundant in the CNS.
To distinguish between effects mediated by 1 and 2 receptors, we initially
administered either the 1 antagonist betaxolol, the 2 antagonist ICI 118,551 (ICI), or a
combination of cort and the 1 or 2 antagonist to wild-type mice shortly before testing
instrumental or contextual fear.

While having no effect on retention latencies for

instrumental fear, betaxolol impaired contextual fear as expected, indicating that the dose
used was sufficient to block 1 receptors (Figures 2.2B and 2.2C). At the same dose, the
2 antagonist ICI did not alter memory retrieval in either test. Notably, co-injection of
cort with the 1 antagonist did not prevent cort-induced impairment of retrieval in either
paradigm.

In contrast, co-administration of cort with the 2 antagonist completely

mitigated cort-induced disruption of memory retrieval in both paradigms.
To determine whether ICI non-specifically elevates freezing when freezing is
relatively low, wild-type mice were conditioned using a less intense shock (0.35 mA) and
saline or ICI was administered 30 min prior to testing. Contextual fear did not differ
between the groups, indicating that ICI does not enhance fear or freezing per se (Figure
2.2D). Finally, because cort acts in the DH to impair retrieval, we predicted that ICI,
when co-infused with cort into the DH, would also block the impairment of retrieval.
Indeed, when infused 15 min prior to testing contextual fear, ICI alone did not affect
retrieval, but it substantially reduced the disruption of retrieval by cort (Figure 2.2E).
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injection of cort with the 1 antagonist betaxolol (Betax) does not. P < 0.01 for the main effect
of treatment on avoidance (6-18/group), and P < 0.001 for the main effect of treatment on
freezing (5-7/group). (D) ICI does not enhance low levels of CF in the absence of cort (45/group). Animals were trained with lower shock intensity (0.35 mA) to approximate cortimpaired freezing. (E) Co-infusion of ICI into the DH prevents disruption of CF by cort. P <
0.001 for the main effect of treatment (4-5/group).

2.3.3 Direct Stimulation of 2 Receptors Impairs Memory Retrieval
Given that a 2 antagonist blocks the effect of cort, we asked whether stimulating
2 receptors would disrupt memory retrieval. Toward this goal, the 2 agonist procaterol
was administered systemically to wild-type mice prior to testing contextual fear. Like
cort, procaterol reduced freezing with a U-shaped dose-response, with 10 g/kg
producing maximum impairment (Figure 2.3A).

Further, the disruption of memory

retrieval by procaterol was blocked by ICI but not the 1 antagonist betaxolol (Figure
2.3B).

Like cort, procaterol did not affect cued fear, indicating that the effect of

procaterol is on contextual memory retrieval rather than fear or freezing per se (Figure
2.3C). Interestingly, at low doses that did not affect memory retrieval when given alone,
combined cort and procaterol treatment significantly impaired retrieval (Figure 2.3D). In
contrast, at doses that maximally affected memory retrieval when given alone, combined
cort and procaterol treatment had no effect on retrieval. In other words, when the drugs
were combined, a U-shaped dose-response was still observed, but with a leftward shift in
potency. Further, contextual memory was also impaired when procaterol or a second 2
agonist, zinterol, was infused into the DH (Figure 2.3E). Finally, an impairment of
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retrieval by procaterol and the block of this effect by ICI but not betaxolol also occurred
in wild-type mice for instrumental fear memory (Figure 2.3F).
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6/group) and IA (7-22/group) retrieval by procaterol (Proc) is blocked by co-administration of
a 2 antagonist (ICI, 1 mg/kg for F), while co-administration of a 1 antagonist (Bet, 1 mg/kg)
does not. P < 0.001 for the main effect of treatment on freezing (B). (C) Procaterol does not
affect retrieval of cued fear (5-8/group). (D) When co-administered, cort and procaterol impair
CF retrieval at considerably lower doses than when either is given individually. P < 0.05 for
the main effect of treatment (4-7/group). (E) Infusion of the 2 agonists procaterol or zinterol
into the DH impairs CF retrieval. P < 0.001 for the main effect of treatment (4-5/group).

2.3.4 Genetic and Interspecies Corroboration that 2 Signaling Mediates
Impairment of Retrieval
To corroborate the pharmacologic data, the effects of cort and procaterol in mice
lacking either 1- or 2-adrenergic receptors were examined for instrumental fear.
Compared to wild-type, both KO lines displayed normal conditioned avoidance, allowing
the examination of drug effects (Figure 2.4A). Cort and procaterol impaired avoidance
similarly in wild-type and 1 KO mice, indicating that 1 signaling is not required for the
disruption of retrieval. In contrast, neither cort nor procaterol impaired avoidance in 2
KOs, indicating that 2 receptors are necessary for impairment.
While our studies utilizing mice were driven in part by the existence of genetic
models, most other animal studies investigating the impairment of memory retrieval by
cort have utilized rats. To determine whether the results implicating 2 receptors in the
impairment of retrieval might be species-specific, rats were treated with the same
pharmacologic reagents that were used in mice. In rats, systemic injections of cort or
procaterol disrupted conditioned avoidance one day after training (Figure 2.4B). While
similar doses of cort (2 mg/kg) reduced retention latencies equally in mice and rats,
somewhat higher doses of procaterol were needed to produce the same degree of
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impairment. Differences in the pharmacologic properties of procaterol could account for
this species-specific difference.

In rats, the effect of cort was blocked by co-

administration of a 2 but not a 1 antagonist, indicating that glucocorticoid disruption of
retrieval via 2 signaling is shared across the two species.
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(A) Cort or procaterol (Proc) disrupts retrieval of IA in 1 KO but not 2 KO mice. P < 0.001 for
the main effect of treatment; P < 0.001 for the main effect of genotype; and P < 0.01 for the
interaction of treatment and genotype (7-10/group). (B) Cort or procaterol impair IA in rats.
Cort-induced disruption of retrieval is prevented by co-administration of the 2 antagonist ICI
but not the 1 antagonist betaxolol (Bet). P < 0.001 for the main effect of treatment (510/group).

2.3.5 Impairment of Memory Retrieval by Stress Requires NE/E and 2 Signaling
Like cort, acute stress disrupts hippocampus-dependent emotional memory
retrieval in rats[123]. To verify and extend these findings, we subjected wild-type mice
to inescapable restraint of various durations 30 min prior to testing contextual fear.
Restraint stress reduced freezing in a U-shaped manner, and at durations of 2 and 5 min,
impaired retrieval to a similar extent as that for treatment with cort or a 2 agonist (Figure
2.5A). To test whether restraint impairs retrieval through a mechanism consistent with
GR activation, mice were pretreated with the GR antagonist Org 34850 (Org) 15 min
prior to administering restraint or cort. At 15 mg/kg, Org partially blocked the effects of
restraint and treatment with 2 mg/kg cort, and completely blocked the effect of 1 mg/kg
cort. At 30 mg/kg, Org fully blocked both restraint- and cort-induced retrieval deficits
(Figure 2.5B). The relatively high systemic doses of Org required are consistent with its
limited CNS penetration[209]. To test whether stress-induced retrieval deficits depend
on 2 signaling, ICI was administered 15 min before restraint. ICI completely blocked
the effects of restraint on retrieval (Figure 2.5C). Further, the elevated levels of plasma
cort observed 30 min following restraint were not reduced by pretreatment with ICI or
Org, indicating that these compounds do not impair the release of cort (Figure 5D).
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Interestingly, plasma levels of cort following stress or cort administration did not
correspond well with the impairment of retrieval. For example, restraint doubled cort
over basal levels, and this level was comparable to that following injection of saline
(Figure 2.5D). Yet restraint impaired retrieval while saline injection did not. Further,
injection of cort at doses that impair retrieval resulted in plasma levels that were 3- to 4fold greater than those for restraint. Naturally, one would expect that restraint stress
activates stress-response systems in addition to that for glucocorticoids. This expectation
led us to test whether NE/E contribute to the impairing effects of restraint on retrieval,
even though the impairing effects of exogenous cort are independent of NE/E. Restraint
significantly impaired retrieval of instrumental fear in wild-type mice (Figure 2.5E). In
contrast, restraint did not impair retrieval in Dbh-/- mice, although there was a trend
toward a small effect. Further supporting of a role for 2 receptors, restraint also did not
impair retrieval in 2 KO mice, although there was also a trend toward a small effect.
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Figure 2.5 Impairment of Memory Retrieval by Stress Depends on GR and 2
Signaling
(A) Inescapable restraint stress 30 min before testing disrupts CF retrieval, with maximal
reduction at intermediate durations. P < 0.01 for the main effect of duration (3-7/group). (B)
Pretreatment with the GR antagonist, Org 34850 (Org, 30 mg/kg), 15 min prior to 2-min
restraint stress or cort prevents disruption of CF retrieval. P < 0.001 for the main effect of
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pretreatment; P < 0.01 for the main effect of treatment; and P < 0.001 for the interaction of
pretreatment and treatment (4-9/group). (C) Pretreatment with the 2 antagonist ICI 15 min
prior to 2-min restraint stress prevents disruption of CF retrieval (4-9/group). (D) Plasma cort
levels rise significantly 30 min after restraint (Res) or the systemic injection of saline or cort
(1 or 2 mg/kg). Pretreatment with either Org (30 mg/kg) or ICI (1 mg/kg) 15 min prior to 2min restraint stress does not prevent the rise in cort.

P < 0.001 for the main effect of

treatment (7-8/group). (E) Restraint stress (2 min) impairs IA retrieval in WT but not Dbh-/- or
2 KO mice.

Mice were either injected with saline or restrained 30 min before testing. P <

0.01 for the main effect of treatment (7-19/group). The only significant post-hoc comparison
between saline and restraint by genotype is for the WT mice.

2.3.6 Corticosterone, 2 Signaling and Stress Impair Retrieval in a Time-limited
Manner
NE, 1, cAMP and PKA signaling all play a time-limited role in hippocampusdependent emotional memory retrieval[92, 153]. For example, NE/E-deficient mice
display deficits in contextual fear 0.1 - 4 days but not 5 or more days after training, and
mice and rats treated with a antagonist show compromised contextual fear and spatial
navigation over a similar time course.

Therefore, we determined whether stress,

glucocorticoids and 2 signaling might also have time-limited effects on retrieval. In
vehicle-injected mice, contextual and instrumental fear did not differ between days 1, 3
and 5 (Figures 2.6A and 2.6B). However, the effects of cort, procaterol and restraint
stress were all time-sensitive, being present on days 1 and 3 after training but absent on
day 5. DH infusion of procaterol or cort 5 days after training also had no effect on
retrieval (Figure 2.6C).
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Figure 2.6 Corticosterone, 2 Signaling and Stress Inhibit Hippocampus-dependent
Memory Retrieval in a Time-limited Manner
(A) Cort (1 mg/kg), procaterol (Proc, 10 g/kg) or restraint (Stress, 2 min) impairs CF
retrieval at 1 and 3 but not 5 days after training. P < 0.001 for the main effect of day; P <
0.001 for the main effect of treatment; and P < 0.01 for the interaction of day and treatment
(4-12/group). (B) Cort (1 mg/kg) or procaterol (10 g/kg) impairs IA retrieval at 1 day,
partially impairs retrieval at 3 days, and does not impair retrieval at 5 days after training. P <
0.001 for the main effect of day; P < 0.05 for the main effect of treatment; and P < 0.05 for
the interaction of day and treatment (7-20/group). (C) Neither infusion of cort nor procaterol
into the DH affects CF retrieval 5 days after training (5/group).

2.3.7 By Coupling to Gi/o Proteins, 2 Opposes the Role of 1 in Retrieval
To obtain more direct evidence that 1 and 2 receptors oppose each other in
retrieval, we asked whether interfering with 2 signaling would rescue retrieval when 1
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signaling was blocked or absent. As expected, retrieval was impaired when wild-type
mice were treated with the 1 antagonist betaxolol shortly before testing contextual fear
one day after training (Figure 2.7A). However, when ICI was combined with betaxolol,
no effect on retrieval was observed, i.e. the 2 antagonist reversed the deficit caused by
the 1 antagonist. Similarly, ICI reversed the retrieval deficits present in 1 KO and
Dbh-/- mice. Lastly, 1/2 double KO mice exhibited normal contextual fear, providing
additional genetic support for the pharmacologic data.
Next, we sought to determine the mechanism by which 2 signaling impairs
retrieval. Although the traditional view is that -adrenergic receptors couple to and
signal via the adenylyl cyclase-stimulatory G protein Gs, there is evidence that 2
receptors can also signal through Gi/o[210-212]. Because cAMP signaling is necessary
and sufficient for contextual memory retrieval mediated by NE and 1 receptors[153], we
asked whether 2 signaling might oppose 1 signaling in retrieval by activating Gi/o and
inhibiting adenylyl cyclase.
To test this idea, pertussis toxin (PTx) was employed because it uncouples Gi/o
proteins from their receptors by ADP-ribosylation of Gi/o. Because PTx can take several
days to be fully effective in the hippocampus in vivo[213, 214], we infused PTx into the
DH one day before fear conditioning to minimize potential effects on acquisition and
consolidation. Mice were tested for retrieval two days after conditioning. Pretreatment
with PTx did not affect retrieval in mice infused with vehicle 15 min before testing
(Figure 2.7B).

Strikingly, however, PTx pretreatment completely prevented the

impairment of retrieval by zinterol, cort and stress.
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A low dose of cort was also

examined to determine whether PTx pretreatment might shift the dose-response
relationship to the left (i.e. more sensitive to cort), but no evidence for this was observed.
Given the results with PTx, we then asked what effect selectively stimulating
either 1 or 2 receptors would have on cAMP levels in the DH. To avoid the potential
confounds of anesthesia and sacrifice on cAMP levels following DH infusion, DH slices
were used. Slices were incubated in aCSF with or without the non-selective  agonist
isoproterenol (Iso). To selectively stimulate 1 receptors, slices from 3 KO mice were
treated with Iso plus the 2 antagonist ICI. To selectively stimulate 2 receptors, slices
from 1/3 double KO mice were treated with Iso. To stimulate both 1 and 2 receptors,
slices from 3 KO mice were treated with Iso. As a control, slices from 1/2/3 triple
KO mice were treated with Iso. Iso had no effect on cAMP in the triple KO slices
(Figure 2.7C). However, Iso at 0.3 - 1 M increased cAMP when selectively stimulating
1 receptors (Figure 2.7E). In contrast, Iso at 0.1 – 1 M caused cAMP to decrease when
selectively stimulating 2 receptor (Figure 2.7D). Finally, when 1 and 2 receptors were
stimulated simultaneously, no increase in cAMP was observed (Figure 2.7F). Taken
together, the results indicate that 1 and 2 receptors functionally oppose one another with
respect to cAMP levels.
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Figure 2.3.7  2 Signaling Opposes 1 Signaling in Retrieval and in cAMP Production
through Gi/o
(A) The impairment of CF retrieval by betaxolol (Bet, 1 mg/kg, 30 min before testing one day
after training) is prevented by concurrent administration of ICI (1 mg/kg). The deficits in CF
retrieval exhibited by 1 KO and Dbh-/- mice one day after training are reversed by treatment
with ICI 30 min before testing. Finally, 1/2 double KO (DKO) mice do not exhibit a deficit in
CF. P < 0.001 for the main effect of group (5-16/group). (B) Infusion of pertussis toxin (PTx,
10 ng) into the DH one day prior to training prevents the impairment of CF retrieval by
restraint, cort (50 ng) or zinterol (100 ng).

Restraint was administered 30 min before and

cort or zinterol was infused 15 min before testing 2 days after training. P < 0.001 for the main
effect of pretreatment; P < 0.001 for the main effect of treatment; and P < 0.001 for the
interaction of pretreatment and treatment (5/group). (C - F) Hippocampal slices were
incubated in aCSF (0) or various concentrations of the non-selective  receptor agonist
isoproterenol (Iso). (C) Non-specific effects of Iso on cAMP were not apparent in slices from
1/2/3 triple KO (TKO) mice (5-10/group). (D) Selective stimulation of 2 receptors by Iso
decreased cAMP in slices from 1/

3

DKO mice. P < 0.05 for the main effect of concentration

(8-18/group). (E) Selective stimulation of 1 receptors by Iso increased cAMP in slices from 3
KO mice treated with the 2 antagonist ICI. P < 0.05 for the main effect of concentration (78/group). (F) Combined stimulation of 1 and 2 receptors by Iso did not alter cAMP in slices
from  3 KO mice (8-10/group).

2.4 DISCUSSION
The goal of this study was to resolve the competing ideas of how NE is required
for the retrieval of hippocampus-dependent emotional memory, yet is also responsible for
the impaired retrieval of such memories by stress and glucocorticoids. Results from the
current studies employing NE/E-deficient Dbh-/- mice indicate that NE/E are not required
for the impairing effects of glucocorticoids per se (Figure 2.2A). This finding is contrary
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to the hypothesis that glucocorticoids impair memory by enhancing the release of
NE[115, 140, 141]. However, NE/E do contribute to the impairing effects of stress, as
evidenced by the attenuation of stress-induced retrieval impairment in Dbh-/- mice (Figure
2.5E). Consistent with this finding, relatively high plasma levels of cort were required to
impair retrieval when cort was administered before testing (Figure 2.5D). In contrast, the
levels of cort following restraint stress were only moderately elevated (about twice
baseline), and were similar to the levels observed following injection of saline, a
procedure that does not impair retrieval. We hypothesized that stress-response systems in
addition to glucocorticoids are engaged following restraint, and that these other factors
synergize with glucocorticoids to impair retrieval. Evidence from Dbh-/- mice indicates
that NE/E are among these factors. Our data using agonists for the two systems indicate
that NE/E and glucocorticoids released during stress may act in concert to impair
retrieval at hormone levels that would be innocuous individually (Figure 2.3D).
Consistent with the above, extracellular levels of NE in the DH are significantly elevated
30 min after restraint stress, whereas they remain unchanged 30 min after intraperitoneal
injection of saline[215, 216].
Despite confirming that glucocorticoids and NE/E contribute to the impairment of
hippocampus-dependent emotional memory retrieval by stress, the mechanisms by which
these factors impair retrieval have been unclear. Prior pharmacologic evidence suggested
that glucocorticoids and NE/E impair retrieval by activating 1-adrenergic receptors[141].
However, additional pharmacologic and genetic evidence indicates that signaling by 1
receptors is required for contextual and spatial memory retrieval[92]. In the current
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study, we found that glucocorticoids impair memory retrieval in the presence of a 1
antagonist (mice and rats) and in 1 KO mice (Figures 2.2 and 2.4), indicating that 1
signaling is not required for the impairment of retrieval. In contrast, we found that low
doses of 2 receptor agonists impair retrieval in mice and rats (Figures 2.3 and 2.4). In
support of a critical role for 2 receptors, the impairing effects of 2 agonists, cort and
stress were greatly reduced both in the presence of a 2 antagonist (mice and rats) and in
2 KO mice (Figures 2.2 – 2.5). Consistent results between rats and mice are important
because nearly all of the prior animal studies on stress, glucocorticoids and memory
retrieval were performed in rats.
The data implicating 1 receptors in the impairment of retrieval were based in part
on the use of the 1-selective agonist xamoterol[141]. In that study, doses of 3 and 10
mg/kg were used to demonstrate retrieval impairment.

In contrast, xamoterol fully

rescues contextual memory retrieval in Dbh-/- mice at 1 mg/kg. We hypothesized that
higher doses of xamoterol activate 2 (as well as 1) receptors, and that the activation of
2 receptors impairs retrieval. In support of this, we have found that the impairment of
retrieval by 6 mg/kg xamoterol is blocked in the presence of a 2 antagonist and in 2 KO
mice, while impairment is unaffected in the presence of a 1 antagonist and in 1 KO
mice (Chapter 3), analogous to the current results for the 2-selective agonist procaterol.
Extrapolating on the above, these results suggest that at the doses used previously[141],
the 1-selective antagonist atenolol also blocks 2 receptors.
Classically, -adrenergic receptors couple to the adenylyl cyclase-stimulating G
protein Gs, and their activation increases cAMP. Given that 1 receptors and cAMP
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signaling in the hippocampus are required for hippocampus-dependent emotional
memory retrieval[92, 153], it was not apparent how activation of 2 receptors in the
hippocampus would impair retrieval.

One possibility was that these two receptor

subtypes are expressed on different cells or in distinct subcellular compartments, where
increases in cAMP would have opposite effects on processes important for retrieval.
However, a second possibility was suggested by recent studies examining signaling by 2
receptors. Evidence suggests that 2 receptors can couple to the pertussis toxin-sensitive,
adenylyl cyclase-inhibiting G protein Gi, and that such coupling can limit or prevent
increases in cAMP in cardiac myocytes[210-212]. In support of such a mechanism,
uncoupling Gi/o proteins from their receptors by PTx pretreatment in the DH blocked the
impairing effects of stress, cort and a 2 agonist on retrieval (Figure 2.7B). Further,
cAMP levels in DH slices were increased by selectively stimulating 1 receptors, but
were decreased by selectively stimulating 2 receptors (Figure 2.7C). Finally, when 1
and 2 receptors were stimulated simultaneously, no changes in cAMP were observed.
Based on the above, the simplest explanation for the impairing effects of stress,
glucocorticoids and 2 signaling is that they oppose the increase in cAMP that is
necessary for retrieval. However, 2 signaling through Gi/o has been linked to effects that
may be independent of a constraint on cAMP levels[217], and it is possible that some of
these effects are also relevant to the impairment of retrieval. Additional studies will be
needed to address this. Highlighting the contrasting roles of these two receptors, 2
signaling in the heart acts to protect cardiomyocytes from excessive 1 stimulation that
can lead to apoptosis and heart failure if unchecked[206, 207].
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Results from many studies have suggested that important interactions underlie the
cognitive effects of cort and NE[195, 196, 218, 219]. Our results suggest that this occurs
at least in part at the level of 2-adrenergic signaling. It is thus of interest to consider
how glucocorticoid signaling might intersect with 2 signaling to impair retrieval.
Glucocorticoid signaling appears to be mediated by a GR-like receptor because
fluticasone mimics the effect of cort and Org 34850 blocks the effect of cort (Figures
2.1C and 2.5A). This is consistent with other studies suggesting a role for GR or GR-like
signaling in the impairment of retrieval[106, 107].

2 signaling appears to be

downstream of glucocorticoid signaling because the 2 antagonist ICI blocks the
impairing effect of cort (Figures 2.2 and 2.4).

However, it is not clear how

glucocorticoid signaling might activate 2 signaling, given that the effect of cort does not
require NE/E (Figure 2.2A). One possibility is that either cort or GR interact directly
with the 2 receptor to cause activation. Another possibility is that cort and GR may
signal through an intermediary that leads to the activation of 2 signaling. In each of
these cases, the 2 receptor would be a key effector for at least some of the rapid, nongenomic effects of glucocorticoids. Alternatively, it is possible that the impairment of
retrieval requires coincident signaling by 2 and GR, a mechanism that would also be
sensitive to 2 blockade. This mechanism seems less likely because exogenous cort
administration in the absence of NE/E impairs retrieval; however, the coincident
signaling model is possible if there is sufficient constitutive signaling at 2 receptors in
the absence of NE/E[220, 221]. The reversal of retrieval impairment by ICI in Dbh-/-
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mice is consistent with the idea that there is some constitutive signaling at 2 receptors
(Figure 2.7A).
Interestingly, cort, fluticasone, procaterol and the combination of cort plus
procaterol all exhibited U-shaped dose-response curves for retrieval impairment when
given systemically (Figures 2.1 and 2.3). These observations are complementary to the
inverted U-shaped dose-response curve reported for the GR agonist RU 28362 in the
enhancement of emotional memory consolidation[136].

These findings suggest that

moderate levels of stress can affect memory, but higher levels of stress actually have less
of an effect. Indeed, we found that 10 min of restraint impaired retrieval less than 2 or 5
min of restraint (Figure 2.5A). The reason why impairment dissipates with higher doses
has not been clear. Interestingly, specific stimulation of 2 receptors by isoproterenol
decreased cAMP in a U-shaped manner, providing potential insight into the above. It is
possible that higher levels of stimulation result in rapid desensitization of 2 signaling, or
that the recruitment of additional signaling pathways by 2 receptors mitigate signaling
induced by lower levels of stimulation. Future studies will be needed to address this.
In addition to the level of stress being an important determinant of whether effects
on memory are observed, our data demonstrate that the duration between acquisition and
retrieval is also an important factor (Figure 2.6). The time course for the effects of stress,
cort and 2 signaling was essentially identical to that for the requirement of NE, 1,
cAMP and PKA signaling in retrieval[92, 153], i.e. an intermediate phase of memory was
susceptible. These findings are consistent with the idea that 2 signaling acts to oppose
the role of 1 signaling in retrieval. The time course data also rule out the possibility that
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stress, cort and 2 signaling affect contextual information processing per se, which would
be independent of the interval between training and testing.
A potentially important aspect of -adrenergic receptor physiology is that NE, the
adrenergic neurotransmitter in the DH, is about an order of magnitude more potent in
activating 1 receptors than 2 receptors[222]. As a result, it seems likely that moderately
arousing conditions would facilitate hippocampus-dependent emotional memory retrieval
through the release of NE that would then activate 1 receptors. Extending this idea,
strongly arousing conditions typical of ―stress‖ would impair memory retrieval through
the release of glucocorticoids and additional NE that together would activate 2 receptors.
Because strongly arousing conditions enhance memory consolidation, this could
temporarily facilitate a shift away from processes favoring retrieval toward those
favoring consolidation.
With respect to consolidation, results from many studies indicate that stimulating
glucocorticoid or adrenergic signaling by exogenous administration of agonists shortly
after conditioning enhances memory retention[77, 195, 196]. These results have often
been interpreted as indicating that glucocorticoid and adrenergic signaling are required
for the enhanced consolidation of emotionally arousing events. In contrast, interfering
with glucocorticoid signaling shortly after training leads to deficits in hippocampusdependent memory consolidation, but does not impair emotional memory in general, such
as cued fear[102, 198]. The current study confirms and extends observations indicating
that adrenergic signaling is not uniquely required for the consolidation of emotional
memory, regardless of whether it depends on the hippocampus. While NE/E-deficient
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Dbh-/- and 1 KO mice exhibit deficits in hippocampus-dependent emotional memory
retrieval, neither Dbh-/-, 1 KO, 2 KO nor 1/2 double KO mice exhibit deficits in the
consolidation of instrumental or Pavlovian fear[92, 93; current study and unpublished
data].

Additional studies will be required to resolve the findings that -adrenergic

signaling is not required for consolidation of these tasks, even though exogenous
stimulation of  signaling is sufficient to enhance consolidation.
The majority of studies examining the roles of -adrenergic signaling in human
cognition have employed the general  receptor antagonist propranolol. Given that 2
signaling can act to oppose 1 signaling, a potentially important corollary derived from
the current studies is that the use of general  receptor agents (e.g. isoproterenol as an
agonist and propranolol as an antagonist) may not readily reveal the distinct roles of
individual  receptors, and the use of these agents may generate results that are complex
or misleading. This idea is support by our pharmacologic and genetic data (Figure 2.7A).
Findings from the current study are likely relevant to common situations in which
stress negatively impacts cognition. Public speaking and examinations testing knowledge
often result in anticipatory arousal and stress that can interfere with cognitive
performance. These tasks usually depend on the retrieval of recently learned or reviewed
information that is likely susceptible to the impairing effects of stress. Interestingly, the
non-selective  antagonist propranolol is reported to enhance performance on
examinations and in cognitive flexibility tasks[166-168]. Our findings suggest that the
effect of propranolol is due to its blockade of the 2 receptor, and that a selective 2
antagonist would be similarly efficacious.
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Finally, one of the hallmarks of PTSD is the intrusive retrieval of memories for
traumatic events. At first pass, results from the current study and other studies suggest
that glucocorticoids, 2 agonists and 1 antagonists might reduce the retrieval of
traumatic memories in PTSD. However, it is possible that these agents would often be
without effect on traumatic memory retrieval because of the limited time window over
which they would reduce retrieval[Figure 6; 92]. Further, hippocampus-independent (e.g.
cued) traumatic memory is likely to be unaffected by these agents. Perhaps the most
promising avenue for treating the intrusive retrieval of traumatic memories in PTSD will
be to interfere with the reconsolidation of these memories following retrieval[169, 223].
Such an approach might be more efficacious than promoting extinction of traumatic
memories because extinction learning is typically context-dependent. Indeed, results
from some studies suggest that  blockers such as propranolol may interfere with the
reconsolidation of aversive memory and reduce symptoms of PTSD[165, 171, 224, 225].

2.5 EXPERIMENTAL PROCEDURES
2.5.1 Subjects
Wild-type, Dbh+/−, Dbh−/−, β1 KO and β2 KO mice were on a hybrid 129/Sv x
C57BL/6 background[91, 226, 227]. β3 KO, β1/β3 double KO and β1/β2/β3 triple KO
mice were on a hybrid FVB/N x 129/Sv x C57BL/6 x DBA/2 background[228]. Mice
were generated by mating either heterozygotes or homozygotes, and genotype was
determined by PCR.

The prenatal loss of Dbh−/− mice was rescued as previously

described[229]. No significant differences in results were found by gender or parental
genotype, so data were combined. Female Fischer 344 rats (Harlan, Indianapolis, IN)
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were 3-4 weeks old upon arrival. Animals were maintained on ad lib food and water and
a 12 h light:dark cycle, with lights on beginning at 07:00. Animals were housed in
relatively small, quiet rooms for 3-4 weeks before studies began to minimize the stress
associated with caretaking and colony management during the light phase. Mice were 36 months old and rats were 7-11 weeks old when tested. Studies were performed during
the light phase, with most experiments taking place between 08:00 - 15:00. Studies were
in accordance with NIH guidelines and had the approval of the IACUC at the University
of Pennsylvania.

2.5.2 Pavlovian Fear Conditioning
Adjacent to the training room, animals were placed in pairs (mice) or singly (rats)
into opaque holding buckets (~12 cm diameter) with bedding and covers for 30-60 min
before being manipulated further. Animals were given a 3-min handling session each day
for 2 days in the training room. Saline was injected at the end of handling each day. On
the following day, training consisted of placing the animal in the conditioning apparatus
(ENV-010MC with ENV-414S, Med Associates, St. Albans, VT) for 2 min, after which
an 84 dB, 4.5 kHz tone was activated for 30 s. Two seconds before the end of the tone, a
2 s, 1 mA footshock was delivered. The animal was returned to its home cage 30 s after
shock. Contextual fear was tested for 5 min in the conditioning apparatus in the absence
of the tone. Cued fear was tested in a context containing distinct visual, tactile, and
olfactory cues. After 2 min, the training tone was turned on for 3 min. Percent freezing
was estimated by scoring the presence or absence of non-respiratory movement every 5 s.
Tests were conducted 1 day after training except where indicated.
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2.5.3 Instrumental Fear Conditioning
Animals were handled as described above. Training consisted of placing a rodent
in the lighted chamber of the apparatus used for Pavlovian conditioning and timing its
latency to fully enter (except for the tail) the dark chamber. Once the animal entered the
dark chamber, the retractable partition separating the two chambers was lowered and a
footshock was delivered for 2 s (0.30 – 0.35 mA for mice, 0.75 mA for rats). After 15 s
the animal was returned to its home cage. Animals that did not enter the dark chamber
after 100 s during conditioning were excluded. Testing was identical to training except
that no shock was delivered and the partition remained up. Latencies to enter the dark
chamber were recorded. If an animal did not enter the dark chamber within 10 min, it
was returned to its cage and assigned a latency of 10 min. Tests were conducted 1 day
after training except where indicated.

2.5.4 Restraint Stress
Mice were handled as described above, except that they were placed individually
into the holding buckets. Mice were immobilized by being placed into ventilated 50 ml
plastic tubes for 2 min (unless noted otherwise), 30 min prior to testing retrieval.

2.5.5 Drugs
Fluticasone, betaxolol HCl, ICI 118,551 HCl, procaterol HCL (Tocris, Ellisville,
MO), corticosterone (Sigma, St Louis, MO) and Org 34850 (Organon, Newhouse, UK)
were administered subcutaneously 30 min before testing for standard conditions, or 45
min before testing when restraint was administered 30 min before testing. Except for
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cort, fluticasone and Org 34850, drugs were dissolved in 0.9% saline (procaterol also
contained 0.1 mg/ml ascorbic acid, pH 7.4, Sigma). Cort and fluticasone were dissolved
in DMF and diluted into saline (0.025-0.3% DMF), while Org 34850 was dissolved in
DMSO. Vehicle was either saline, saline containing 0.1 mg/ml ascorbic acid, saline
containing 0.3% DMF, or 100% DMSO. Injection volumes were 10 l/g except for Org
34850 and DMSO, which were 2 l/g. Zinterol HCl and pertussis toxin (Tocris) were
dissolved in 0.9% saline (zinterol also contained 0.1 mg/ml ascorbic acid, pH 7.4) and
infused into the DH. For DH infusion, cort was dissolved in DMF and diluted into saline
(0.1-1% DMF).

2.5.6 Dorsal Hippocampus Infusion
A double guide cannula (C235 system, Plastics One, Roanoke, VA) was
implanted under pentobarbital anesthesia (72.5 mg/kg ip) using a stereotax
(SAS75/EM40M, Cartesian Research, Sandy, OR).

The guide was placed 1.7 mm

posterior to Bregma and 1.5 mm bilateral for DH infusions. The guide projected 1.5 mm
below the base and the dummy cannula extended 0.5 mm below the guide. One week
after surgery, bilateral infusions were made into conscious mice while gently holding the
nape of the neck.

The dual injection cannula extended 0.9 mm below the guide.

Infusions were 0.5-1 μl/side at 0.4 μl/min, with the injection cannula being left in place
for 30 s before the mouse was returned to its home cage. Because studies indicate that
the effects of PTx are best evaluated 3 days after infusion, PTx was infused 3 days before
testing (i.e. 1 day before training, which was 2 days before testing). A pilot study
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indicated that 1 ng and 10 ng PTx (comparable to or lower than what has been used by
others) were similarly effective.

2.5.7 Corticosterone Levels
Mice were handled for two days as described above. Between 08:00 and 11:00 on
the third day, some mice were either left untreated or received an injection of vehicle or
cort 30 min before retro-orbital blood collection using heparin-coated capillary tubes.
Other mice were subjected to 2 min of restraint stress 30 min before collection. These
mice were pretreated with either vehicle, 1 mg/kg ICI or 15-30 mg/kg Org 34850 15 min
before restraint. Blood was placed on ice and then spun at 2,000g at 4°C for 5 min and
plasma was stored at -80°C. Cort was measured in duplicate by [125I]-radioimmunoassay
(MP Biomedicals, Orangeburg, NY) according to instructions.

2.5.8 cAMP Levels
Mice were decapitated without anesthesia and the brain was rapidly removed and
chilled in ice-cold artificial cerebral spinal fluid (aCSF) containing sucrose as
described[92]. Brain slices transverse to the DH were cut at 400 m and DH slices were
surgically isolated and allowed to recover for at least 1 h at 37°C in oxygenated regular
aCSF. Slices were then transferred to a second chamber containing isoproterenol (and
0.1 M ICI for selective stimulation of 1 receptors in 3 KO slices) in oxygenated aCSF
at 37°C for 2 min, after which they were immediately placed on ice in 0.15 ml 6% TCA
with ~4,000 cpm of [3H]-cAMP (adenosine 3′, 5′-cyclic phosphate, ammonium salt, [2,83

H]; PerkinElmer, Waltham, MA) and then homogenized using a Sonic Dismembrator
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100 (Fisher, Pittsburgh, PA). Pilot experiments indicated that 5 min incubations provided
similar results to those for 2 min incubations, while 1 min incubations provided similar
results or did not affect cAMP. Pilot incubations with 10 nM isoproterenol were without
effect on cAMP and are not shown. Extracts were centrifuged at 2,500g at 4°C for
15 min, and the pellet was stored at -80°C for subsequent Bradford assay to determine
total protein. Supernatants were extracted four times with 0.6 ml water-saturated ether,
evaporated, reconstituted in 1 ml assay buffer and stored at -20°C.

Recovery was

assessed by measuring the amount of [3H]-cAMP in each sample, which ranged from 6080%.

To determine cAMP levels, a [125I]-radioimmunoassay (PerkinElmer) was

employed using 100 l of undiluted sample in duplicate according to instructions for the
non-acetylated procedure. On the basis of the Bradford assays, percent recoveries and
standard curves, a cAMP level (pmol /mg protein) was calculated for each slice. For each
genotype, the mean for the slices incubated in aCSF alone was normalized to 100%.
Actual values were (in pmol/mg protein): 102 ± 11 for 1/2/3 triple KO, 95 ± 15 for
1/3 double KO, 88 ± 7 for 3 KO, and 109 ± 18 for 3 KO with 0.1 M ICI.

2.5.9 Statistics
Data were analyzed with Statistica 9.0 (StatSoft, Tulsa, OK) using one- or twoway ANOVA. Post-hoc comparisons were made using Fisher’s LSD. Data are presented
as mean ± standard error. For all figures, * indicates P < 0.05, ^ indicates P < 0.01, and #
indicates P < 0.001. Comparisons marked as significant are to the reference group except
where indicated.
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3.1 ABSTRACT
Xamoterol, a partial 1-adrenergic receptor agonist, has been reported to impair
the retrieval of hippocampus-dependent spatial reference memory in rats. This finding is
in contrast to the observation that xamoterol restores memory retrieval in gene-targeted
mice lacking norepinephrine (NE) and in a transgenic mouse model of Down syndrome
in which NE is reduced. Restoration of retrieval by xamoterol in these two models
complements the observation that NE and 1 signaling are required for hippocampusdependent retrieval of contextual and spatial reference memory in wild-type mice and
rats. Additional evidence indicates that cAMP-mediated PKA and Epac signaling are
required for the retrieval of hippocampus-dependent memory.

As a result, we

hypothesized that xamoterol has effects in addition to the stimulation of 1 receptors that,
at higher doses, act to counter the effects of 1 signaling.

Using Pavlovian and

instrumental fear conditioning, as well as pharmacologic and genetic approaches to
manipulate -adrenergic signaling, we report that xamoterol-induced disruption of
memory retrieval depends on 2-adrenergic receptor signaling.

Interestingly, the

impairment of memory retrieval by xamoterol is blocked by pertussis toxin pretreatment,
suggesting that 2 signaling opposes 1 signaling during memory retrieval at the level of
G protein and cAMP signaling. Finally, similar to the time-limited roles for NE, 1 and
cAMP signaling in hippocampus-dependent memory retrieval, xamoterol only impairs
retrieval for several days after training. We conclude that the disruption of memory
retrieval by xamoterol is mediated by Gi/o-coupled 2 signaling, which opposes the Gs
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coupled 1 signaling that is transiently required for hippocampus-dependent emotional
memory retrieval.

3.2 INTRODUCTION
As the registrar of our personal experiences, episodic memory is one of the
hallmarks of identity. Among the neural systems that underlie episodic memory, the
hippocampus is central. Bilateral damage to the hippocampus can eliminate the ability to
form new episodic memories, as well as impair the ability to recall recent but not remote
episodic memories[230, 231]. Many of our most influential episodic memories are
derived from events rich with emotion that can range from ecstatic to traumatic. While
the vast majority of these memories are beneficial and/or prized, intense, psychologically
traumatic experiences can lead to psychiatric problems such as post-traumatic stress
disorder (PTSD).

In fact, dysregulation of episodic memory is one of the cardinal

symptoms in PTSD patients, who often suffer from recurrent, intrusive memories of
traumatic events[232]. Frequent retrieval of such memories can be debilitating due to the
fear and anxiety they invoke.
For this and other reasons, the mechanisms underlying the consolidation, retrieval
and reconsolidation of episodic memory are of great interest.

Many studies have

contributed to our understanding of the molecular and cellular signaling pathways
important for episodic memory consolidation[3, 233-235]. In addition, some studies have
begun to illuminate signaling pathways required for the retrieval of episodic
memory[236, 237]. As a result, it has been suggested that the consolidation and retrieval
of hippocampus-dependent memory have common neurobiologic substrates and signal
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transduction pathways. As an example, nearly four decades of research across species
illustrate that agents that acutely elevate cAMP (cyclic 3’,5’-adenosine monophosphate)
usually enhance memory consolidation, whereas agents that block cAMP signaling
impair consolidation[3, 234].
Recent evidence suggests that cAMP signaling is also involved in hippocampusdependent memory retrieval. Bilateral infusion of a cAMP antagonist into the dorsal
hippocampus (DH) of rats 10 min before testing inhibitory avoidance one day after
training reduces step-down latency[154]. Further, signaling by norepinephrine (NE)
through the 1-adrenergic receptor is required for the retrieval of an intermediate phase of
hippocampus-dependent memory[92]. Mice with targeted disruption of the gene for the
1 receptor (1 KO) display deficits in contextual fear, and systemic administration of the
1 antagonist betaxolol produces retrieval deficits in wild-type mice and rats. These
effects are reproduced by infusion of the 1-selective antagonist atenolol into the DH. 1
receptors couple to the adenylyl cyclase stimulatory G protein, Gs, and their activation is
predicted to elevate cAMP levels in the DH. Consistent with this idea, cAMP antagonists
impair retrieval when infused into the DH shortly before testing contextual fear, and DH
infusion of cAMP agonists rescues retrieval in gene-targeted mice lacking NE[153].
Further, activation of at least two targets of cAMP signaling, protein kinase A (PKA) and
the exchange protein activated by cAMP (Epac), is also required for hippocampusdependent memory retrieval. Finally, transgenic mice expressing an invertebrate, Gscoupled octopamine receptor exhibit both octopamine-dependent increases in DH cAMP
and enhancement of contextual fear memory retrieval[238].
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In contrast to the above, it has been reported that stimulation of 1 receptors
impairs memory retrieval. In rats, infusion of the 1-selective antagonist atenolol blocks
the impairing effects of a glucocorticoid agonist on retrieval of spatial reference
memory[141]. In support of this, injection of 3 or 10 mg/kg of the partial 1 agonist
xamoterol decreases spatial reference memory retrieval. The authors conclude that the
impairment of hippocampus-dependent memory retrieval by glucocorticoids and
xamoterol involves the activation of 1-coupled cAMP signaling. This observation is
surprising because administration of xamoterol at 1-3 mg/kg fully rescues contextual
memory retrieval in gene-targeted NE-deficient mice, suggesting that 1 signaling is
sufficient for the role of NE in retrieval[92].
Atenolol received approval for use in U.S. patients in 1981 and is currently used
to treat congestive heart failure and hypertension. Clinical application of xamoterol began
in the 1980’s and is prescribed today as a cardiac stimulant and hypotensive agent[244246]. In the late 1970s – early 1990s, radiolabeled agents shown to block receptors with
high affinity and decent selectivity were used to first localize and quantify -AR subtypes
in tissues including the heart, lung, spleen and cerebral cortex[247]. The ability of
agonists (xamoterol), agonists (procaterol, zinterol), antagonists (atenolol,
betaxolol) and antagonists (ICI 118551) to displace agents like 3H-DHA and 125I-CYP
became a widely used method of determining specificity of these agents (125I-CYP also
binds 5-HT receptors)[243, 248, 249].
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Several studies have demonstrated modest specificity for xamoterol and atenolol in CNS
ex vivo preparations[243, 248, 249]. For example, xamoterol shows 10-fold specificity
for vs. receptors, which is all right considering that antagonists at receptors
display 4-6 times greater selectivity[243, 248, 249]. Unfortunately, xamoterol is still
amongst the most selective agonists available, limiting its ability to study selective
effects pertaining to learning and memory and diminishing its ability to treat heart disease
because of concurrent  effects on the vasculature[245]. Likewise, atenolol’s selectivity
for  is rather pedestrian (15-29 fold preference for vs. )[248, 249]. In contrast,
betaxolol displays a 2.2 log differential at opposed to , supporting its superiority as a
 antagonist when directly compared to atenolol[248]. Moreover, within-study
comparison of atenolol with other  antagonists illustrates that atenolol is much less
selective than several  blockers (acebutolol, practolol, I-metoprolol)[248, 249].
Betaxolol is amongst the most-specific, supporting its utility to selectively block 
receptors in order to discriminate between xamoterol’s effects at and -ARs.
[Notably, ICI 118,551 displays a 100 fold selectivity for  and is amongst the most
selective  antagonists available][248].
The goal of this study, then, was to resolve the seemingly conflicting observations
that 1 signaling is required for hippocampus-dependent memory retrieval and is also
responsible for the impairment of retrieval. Of note, somewhat higher doses of xamoterol
were needed to impair retrieval in wild-type rats as compared to those needed to rescue
retrieval in mutant mice.

This could be due to differences in genetics, species or

mechanisms, for example. To address this, we first confirmed that xamoterol impairs
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memory retrieval in wild-type mice, making a difference between species unlikely. As a
result, we hypothesized that the pharmacologic characterization of xamoterol-induced
retrieval impairment was incomplete, and that another adrenergic receptor might mediate
this effect. In this study, animals were tested in both Pavlovian and instrumental fear
conditioning paradigms.

Xamoterol and other pharmacologic reagents previously

untested in these paradigms were administered to wild-type mice, as well as to mice
genetically modified to lack either 1- or 2-adrenergic receptors. Our results provide
substantial and unexpected evidence that signaling by Gi/o-coupled 2-adrenergic
receptors in the hippocampus mediates xamoterol-induced impairment of memory
retrieval.

3.3 MATERIALS AND METHODS
3.3.1 Subjects
Wild-type, β1 KO and β2 KO mice were on a hybrid 129/Sv x C57BL/6
background, and were derived by mating either heterozygotes or homozygotes[226, 227].
Gender and parental genotype did not affect the results, so data were combined.
Genotype was determined by PCR. Mice were maintained on ad lib food and water and a
12 h light:dark cycle, with lights on beginning at 07:00.

Animals were housed in

relatively small, quiet rooms for 3-4 weeks before studies began to minimize the stress
associated with caretaking and colony management during the light phase. Mice were 36 months old when tested. Studies were performed during the light phase, with most
experiments taking place between 08:00 - 15:00. Studies were in accordance with NIH
guidelines and had the approval of the IACUC at the University of Pennsylvania.
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3.3.2 Pavlovian Fear Conditioning
Adjacent to the training room, animals were placed in pairs into opaque holding
buckets (~12 cm diameter) with bedding and covers for 30-60 min before being
manipulated further. Animals were given two 3-min handling sessions over 2 days in the
training room. Saline was injected at the end of handling each day. Training consisted of
placing the animal in the conditioning apparatus (ENV-010MC with ENV-414S, Med
Associates, St. Albans, VT) for 2 min, after which an 84 dB, 4.5 kHz tone was activated
for 30 s. Two seconds before the end of the tone, a 2 s, 1 mA footshock was delivered.
The animal was returned to its home cage 30 s after shock. Contextual fear was tested for
5 min in the conditioning apparatus in the absence of the tone. Cued fear was tested in a
context containing distinct visual, tactile and olfactory cues. After 2 min, the training
tone was turned on for 3 min. Percent freezing was estimated by scoring the presence or
absence of non-respiratory movement every 5 s. Tests were conducted 1 day after
training except where indicated.

3.3.3 Instrumental Fear Conditioning
Animals were handled as described above. Training consisted of placing a rodent
in the lighted chamber of the apparatus used for Pavlovian conditioning and timing its
latency to enter (except for the tail) the dark chamber. Once the animal entered the dark
chamber, the retractable partition separating the two chambers was lowered and a shock
was delivered for 2 s (0.30-0.35 mA). After waiting 15 s, rodents were returned to their
home cage. Animals that didn’t enter the dark chamber after 100 s during conditioning
were excluded. Testing was identical to training except that no shock was delivered and
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the partition remained up. Latencies to enter the dark chamber were recorded. If an
animal did not enter the dark chamber within 10 min, it was returned to its cage and
assigned a latency of 10 min. Tests were conducted 1 day after training except where
indicated.

3.3.4 Drugs
Betaxolol HCl, ICI 118,551 HCl and/or xamoterol hemifumarate (Tocris,
Ellisville, MO) were dissolved in 0.9% saline and administered subcutaneously 30 min
before testing. For DH infusion, xamoterol and pertussis toxin (Tocris) were dissolved in
0.9% saline.

3.3.5 Dorsal Hippocampus Infusion
A double guide cannula (C235 system, Plastics One, Roanoke, VA) was
implanted under pentobarbital anesthesia (72.5 mg/kg ip) using a stereotax
(SAS75/EM40M, Cartesian Research, Sandy, OR). The guide was placed −1.7 mm AP
and 1.5 mm bilateral for DH infusions. The guide projected 1.5 mm below the base and
the dummy cannula extended 0.5 mm below the guide. One week after surgery, bilateral
infusions were made into conscious mice while gently holding the nape of the neck. The
dual injection cannula extended 0.9 mm below the guide. Infusions were 1 μl/side at 0.4
μl/min, and the injection cannula was left in place for 30 s before the mouse was returned
to its home cage.

Because studies indicate that the effects of PTx are best evaluated 3

days after infusion[213, 214], PTx was infused 3 days before testing (i.e. 1 day before
training, which was 2 days before testing).
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3.3.6 Statistics
Data were analyzed with Statistica 9.0 (StatSoft, Tulsa, OK) using one- or twoway ANOVA. Post-hoc comparisons were made using Fisher’s LSD. Data are presented
as mean ± standard error. For all figures, * indicates P < 0.05, ^ indicates P < 0.01, and #
indicates P < 0.001. Comparisons marked as significant are to the reference group except
where indicated.

3.4 RESULTS
3.4.1 Xamoterol Impairs Hippocampus-dependent Memory Retrieval
To confirm the impairing effects of xamoterol on hippocampus-dependent
memory retrieval, mice were trained using either Pavlovian or instrumental fear
conditioning. When 1 or 6 mg/kg of xamoterol was administered 30 min prior to testing,
wild-type (WT) mice showed reduced contextual freezing and shorter avoidance latencies
one day after training (Fig. 3.1A & 3.3A).
To determine if xamoterol acts directly in the hippocampus to impair retrieval,
cannulae were implanted in mice so that bilateral DH infusions could be performed. One
week after surgery, cannulated mice were fear conditioned. One day later either saline or
xamoterol was infused 15 min before testing. Xamoterol decreased contextual freezing
with a maximal effect at 10 g (Fig. 3.1B).
To assess whether xamoterol-induced impairment of contextual fear was specific
to memory retrieval, xamoterol (6 mg/kg) was administered 30 min prior to testing cued
fear 1 day after training. Xamoterol did not affect cued fear expression, indicating that it
does not alter fear or freezing per se (Fig. 3.1C).
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FIGURE 3.1 Xamoterol Impairs Hippocampus-dependent Memory Retrieval
(A) Mice were fear conditioned and one day later vehicle or xamoterol was administered
subcutaneously 30 min before testing contextual fear. Systemic xamoterol caused of dosedependent impairment (4-10/group, P < 0.001 for the main effect of dose). (B) Bilateral
cannulae targeting the DH were implanted in mice.

One week later the mice were fear

conditioned, and on the following day they were tested for contextual fear. DH infusions were
performed 15 min before testing.

DH xamoterol caused of dose-dependent impairment (4-

6/group, P < 0.05 for the main effect of dose). (C) Mice were fear conditioned and one day
later vehicle or xamoterol was administered subcutaneously 30 min before testing auditory
fear. Xamoterol did not affect cued fear expression, indicating that it does not alter fear or
freezing per se (5-8/group, P > 0.9). For all figures: *, P < 0.05; ^, P < 0.01; #, P < 0.001
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for post-hoc comparisons, and systemic injections occurred 30 min prior to testing one day
after training unless stated otherwise.

3.4.2 Pharmacologic Evidence that Xamoterol Disrupts Retrieval through 2- and
not 1-adrenergic Signaling
The above data indicate that 0.6 mg/kg xamoterol does not impair contextual
memory retrieval. In comparison, 0.3 mg/kg xamoterol induces significant rescue of
contextual memory retrieval in NE-deficient Dbh-/- mice[92]. This difference could be
the result of a potentially greater sensitivity to 1-adrenergic agonists in Dbh-/- mice.
Alternatively, the impairment of retrieval could be due to effects of xamoterol that are
independent of 1 signaling. In this regard, a closely related receptor to 1 is the 2adrenergic receptor. To test the idea that higher doses of xamoterol might stimulate 2
receptors, a selective antagonist of 2 receptors (ICI 118,551) was employed.

In

agreement with previous results[92], 1 mg/kg ICI 118,551 had no effect on contextual
memory retrieval 1 day after training (Fig. 3.2A). However, co-injection of the 2
antagonist with xamoterol (6 mg/kg) blocked the impairment of contextual fear in a dosedependent manner, with 1 mg/kg ICI producing full rescue of retrieval (Fig. 3.2A). To
determine whether ICI non-specifically elevates freezing when freezing is relatively low,
mice were conditioned using a less intense shock (0.35 mA) and saline or ICI was
administered 30 min prior to testing. Contextual fear did not differ between the groups,
indicating that ICI does not enhance fear or freezing per se (Fig. 3.2B).
In the above experiments, the use of contextual fear was limited by the fact that 1
antagonists impair contextual memory retrieval on their own. To directly compare the
effects of 1 and 2 antagonists on the retrieval impairment induced by xamoterol, mice
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were subjected to instrumental fear conditioning. Similar to the results for contextual
fear, 1 mg/kg ICI did not reduce retention latencies; however, it completely prevented the
impairment in retrieval induced by xamoterol (Fig. 3.2C). Further, the selective 1
antagonist betaxolol (1 mg/kg) did not affect retention latencies when administered alone.
In addition, betaxolol did not prevent xamoterol-induced disruption of inhibitory
avoidance (Fig. 3.2C), even though 1 mg/kg betaxolol is a maximally effective dose for
blocking the retrieval of contextual fear memory[92].
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(A) Co-injection of xamoterol (Xam, 6 mg/kg) with the 2 antagonist ICI 118,551 (ICI, mg/kg)
blocked xamoterol-induced impairment of contextual fear, with 1 mg/kg ICI completely
preventing disruption of retrieval. ICI (1 mg/kg) alone had no effect on retrieval (4-6/group, P
< 0.01 for the main effect of treatment). (B) ICI does not enhance low levels of contextual
fear in the absence of xamoterol (4-5/group, P > 0.9). Animals were trained with lower shock
intensity (0.35 mA) to approximate xamoterol-impaired freezing.

(C) Xamoterol (6 mg/kg)

reduced retention latencies for inhibitory avoidance relative to saline (Sal). Co-administration
of xamoterol with ICI (1 mg/kg) prevented xamoterol-induced disruption of avoidance, while
co-injection of xamoterol with the 1 antagonist betaxolol (Bet, 1 mg/kg) failed to prevent
disruption of retrieval. Neither Bet nor ICI altered avoidance when administered alone (622/group, P < 0.01 for the main effect of treatment).

3.4.3 Genetic Evidence that Xamoterol Disrupts Retrieval through 2- and not 1adrenergic Signaling
We sought to confirm the pharmacologic evidence suggesting that xamoterol is
operating through 2 and not 1 receptors to impair retrieval. Toward this goal, we
examined the effects of xamoterol on retrieval in mice lacking either 1- or 2-adrenergic
receptors. Instrumental fear conditioning was used because 1 KOs exhibit impaired
contextual memory retrieval[92]. 1 KO and 2 KO mice displayed normal retention
latencies when treated with saline, which allowed for the examination of drug affects
(Fig. 3.3A-C). In WT mice, xamoterol significantly reduced avoidance latencies at 1 and
6 mg/kg. Importantly, xamoterol did not reduce retention latencies in 2 KOs at any of
these doses, indicating that 2 signaling is necessary for the effects of xamoterol on
retrieval. In contrast, xamoterol at 0.3 and 1 mg/kg impaired avoidance in 1KOs,
indicating that 1 signaling is not required for the disruption of retrieval by xamoterol.
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Interestingly, there was about a three-fold leftward shift in the U-shaped dose-response
curve for xamoterol in the absence of 1 receptors.
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FIGURE 3.3 Genetic Evidence that  2 Signaling Mediates the Impairment of Memory
Retrieval by Xamoterol
(A) Xamoterol at 1 or 6 mg/kg maximally disrupted avoidance in WT mice (7-10/group, P <
0.05 for the main effect of dose). (B) Xamoterol at 0.3 and 1 mg/kg maximally disrupted
avoidance in 1 KO mice (9-24/group, P < 0.05 for the main effect of dose). (C) Xamoterol did
not impair avoidance at any dose when tested in 2 KO mice, indicating that 2 activation is
required for xamoterol-induced disruption of memory retrieval (7-9/group, P > 0.7 for the
main effect of dose).
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3.4.4 Pertussis Toxin Blocks the Impairing Effects of Xamoterol on Retrieval
The traditional view is that -adrenergic receptors couple to and signal via the
adenylyl cyclase-stimulatory G protein Gs. However, there is evidence that 2 receptors
can also signal through Gi/o[210-212].

Because cAMP signaling is necessary and

sufficient for contextual memory retrieval mediated by NE and 1 receptors[153], we
asked whether 2 signaling might oppose 1 and Gs signaling in retrieval by activating
Gi/o.
To test this idea, pertussis toxin (PTx) was employed because it uncouples Gi/o
proteins from their receptors by ADP-ribosylation. Because PTx can take several days to
be fully effective in the hippocampus in vivo[213, 214], PTx was infused into the DH one
day before fear conditioning to minimize potential effects on acquisition and
consolidation. Mice were tested for retrieval two days after conditioning. Pretreatment
with PTx did not affect retrieval in mice infused with vehicle 15 min before testing (Fig.
3.4). Strikingly, however, PTx pretreatment completely prevented the impairment of
retrieval induced by xamoterol.
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FIGURE 3.4 Gi/o Signaling is Required for the Impairment of Retrieval by Xamoterol
Bilateral cannulae targeting the DH were implanted in mice, and one week later the mice were
infused with either saline (Sal) or pertussis toxin (PTx, 10 ng/side) into the DH. The next day
the mice were fear conditioned, and two days later the mice were infused with either saline or
xamoterol (Xam, 10 g/side) into the DH. Contextual fear was tested 15 min later. Pertussis
toxin pretreatment blocked the impairing effect of xamoterol on retrieval, indicating that this
effect is mediated by the Gi/o class of G proteins (5/group, P < 0.05 for the main effect of
treatment, and P < 0.05 for the interaction between pretreatment and treatment).

3.4.5 Xamoterol Impairs Hippocampus-dependent Memory Retrieval in a Timelimited Manner
NE, 1, cAMP and PKA signaling all play a time-limited role in hippocampusdependent emotional memory retrieval[92, 153]. NE-deficient mice display deficits in
contextual fear 0.1 - 4 days but not 5 or more days after training, and mice and rats
treated with a antagonist show compromised contextual fear and spatial navigation over
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a similar time course. Therefore, we determined if 2 signaling mediated by xamoterol
might also have time-limited effects on retrieval. Contextual fear did not differ between
days 1, 3 and 5 in vehicle-injected animals (Fig. 3.5). However, the effects of xamoterol
were time-sensitive, with animals displaying the greatest impairment 1 day after training,
less impairment 3 days after training and no impairment 5 days after training. The results
indicate that xamoterol affects an intermediate phase of memory retrieval but not
contextual information processing per se.
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FIGURE 3.5 Xamoterol Impairs Hippocampus-dependent Memory Retrieval in a Timelimited Manner
Xamoterol was administered 30 min prior to testing at 1, 3 or 5 days after training.
Xamoterol impaired contextual fear at 1 and 3 but not 5 days after training (5-10/group, P <
0.001 for the main effect of treatment, P < 0.001 for the main effect of day, and P < 0.001 for
the interaction between treatment and day).
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3.5 DISCUSSION
A role for NE and 1-adrenergic signaling in hippocampus-dependent emotional
memory retrieval is supported by multiple experimental outcomes. NE-deficient Dbh-/mice exhibit impaired retrieval of contextual and spatial reference memory, and
contextual memory retrieval is rescued in these mice by the administration of the 1selective agonist xamoterol[92, 93]. Further, 1 KO mice exhibit impaired contextual
memory retrieval, as do wild-type mice treated with one of several 1 antagonists. In
addition, the locus coeruleus has been found to degenerate in people with Down
syndrome[239, 240]. In mouse models of Down syndrome such as Ts65Dn, there is less
brain NE, fewer locus coeruleus adrenergic neurons and more  receptor-positive neurons
in the hippocampus, suggesting the presence of functional NE deficiency[241, 242].
Similar to Dbh-/- mice, Ts65Dn mice display deficits in contextual fear memory retrieval
but not in cued fear memory, and administration of a NE precursor or the 1-selective
agonist xamoterol reverses the impairment of memory retrieval in Ts65Dn mice[242].
The goal of this study was to resolve the conflicting ideas that 1 signaling is
required for the retrieval of hippocampus-dependent emotional memory as outlined
above, and is also responsible for the impaired retrieval of such memories by
xamoterol[141]. In Roozendaal et al., doses of 3 and 10 mg/kg were used to demonstrate
retrieval impairment. In contrast, xamoterol rescues contextual memory retrieval in NEdeficient Dbh-/- mice at 0.3 and 1 mg/kg. The potency of xamoterol for 1 versus 2
receptors is ~10-fold in rat tissue ex vivo and at mouse adrenergic receptors in vitro[92,
243]. As a result, we hypothesized that the higher doses of xamoterol activate 2 as well
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as 1 receptors, and that the activation of 2 receptors impairs retrieval. In the current
study, we found that xamoterol impairs memory retrieval in the presence of a 1
antagonist and in 1 KO mice (Figs. 3.2C and 3.3B), indicating that 1 signaling is not
required for the impairment of retrieval by xamoterol. In contrast, we found that the
impairing effects of xamoterol were greatly reduced both in the presence of a 2
antagonist and in 2 KO mice (Figs. 3.2 and 3.3C). These results demonstrate that
xamoterol impairs retrieval through the stimulation of 2 receptors. In support of a
critical role for 2 receptors, we have also found that low doses of the 2 receptor
agonists procaterol and zinterol impair memory retrieval in mice and rats (Chapter 2).
Classically, -adrenergic receptors couple to the adenylyl cyclase-stimulating G
protein Gs, and their activation increases cAMP levels. Given that 1 receptors and
cAMP signaling in the hippocampus are required for hippocampus-dependent emotional
memory retrieval[92, 153], it was not apparent how activation of 2 receptors in the
hippocampus would impair retrieval.

One possibility was that these two receptor

subtypes are expressed on different cells or in distinct subcellular compartments, where
increases in cAMP would have opposing effects on processes important for retrieval.
However, a second possibility was suggested by recent studies examining signaling by 2
receptors. Evidence suggests that 2 receptors can couple to the pertussis toxin-sensitive,
adenylyl cyclase-inhibiting G protein Gi, and that such coupling can limit or prevent
increases in cAMP in cardiac myocytes[210-212]. In support of the relevance for such a
mechanism in memory retrieval, uncoupling Gi/o proteins from their receptors by PTx
pretreatment of the DH blocked the impairing effect of xamoterol (Fig. 3.4).
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Based on the above, the simplest explanation for the impairing effects of
xamoterol is that they oppose the increase in cAMP that is necessary for retrieval. This
idea is consistent with the observation that xamoterol was more potent at impairing
memory retrieval in 1 KO mice as compared to wild-type mice (Fig. 3.3). In other
words, when both receptors are present, higher levels of 2 stimulation are required to
offset the stimulation of 1 receptors.

With regard to the mechanism of retrieval

impairment, 2 signaling through Gi/o has been linked to effects that may be independent
of or in addition to a constraint on cAMP levels[217], and it is possible that some of these
effects are also relevant to the impairment of retrieval. Additional studies will be needed
to address this. Highlighting the contrasting roles of these two receptors, 2 signaling in
the heart acts to protect cardiomyocytes from excessive 1 stimulation that can lead to
apoptosis and heart failure if unchecked[206, 207].
Interestingly, our data demonstrate that the duration between acquisition and
retrieval is an important factor for determining the extent of retrieval impairment (Fig.
3.5). The time course for the effects of xamoterol on retrieval was essentially identical to
that for the requirement of NE, 1, cAMP and PKA signaling in retrieval[92, 153], i.e. an
intermediate phase of memory was susceptible. These findings are consistent with the
idea that 2 signaling acts to oppose the role of 1 signaling in retrieval.
A potentially important aspect of -adrenergic receptor physiology is that NE, the
adrenergic neurotransmitter in the DH, is an order of magnitude more potent in activating
1 receptors than 2 receptors[222]. As a result, it seems likely that moderately arousing
conditions would facilitate hippocampus-dependent emotional memory retrieval through
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the release of NE and activation of 1 receptors. Extending this idea, strongly arousing
conditions typical of ―stress‖ would impair memory retrieval through the release of
additional NE and also glucocorticoids that together would activate 2 receptors. Other
studies have demonstrated that glucocorticoids impair hippocampus-dependent emotional
memory retrieval[123, 124].

Studies from our lab indicate that this effect of

glucocorticoids is mediated by activation of the 2 receptor, and that NE and
glucocorticoids synergize to activate this receptor at doses that would be ineffective when
present individually (Chapter 2). Because strongly arousing conditions enhance memory
consolidation, this could facilitate a temporary shift away from processes favoring
retrieval toward those favoring consolidation.
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4.1 ABSTRACT
Similar to 1 receptors, additional receptors can influence fear memory.
Pharmacologic and genetic evidence support a transient and novel role for 2 signaling in
intermediate-term hippocampus-dependent memory retrieval, identical to the time-course
of retrieval impairment exhibited by NE, 1, cAMP, PKA and Epac signaling[92, 153].
Moreover, 2 signaling may function in the maintenance of short-term aversive memory.
Conversely, multiple experimental outcomes do not support a general requirement for 2
signaling in the long-term acquisition, consolidation or retrieval of emotional memory.
The finding that 2 agonists and antagonists impair retrieval to a similar extent suggests
that specific confirmation(s) of the 2 receptor might be imperative in affecting retrieval
processes. This is supported by evidence that glucocorticoids may impair recall through
either direct interaction with the 2 receptor, inducing conformational changes in 2 that
prevent signaling necessary for retrieval, or through coincident signaling between 2 and
GR. Moreover, 3 receptors can influence retrieval processes and receptor interactions
may influence the extent of retrieval deficits displayed. Finally, the net effect of
receptor stimulation (or antagonism) on hippocampal cAMP signaling may determine
the degree of retrieval impairment expressed, as individual receptors can have similar
or opposing effects on cAMP levels.

4.2 INTRODUCTION
Over the last decade, it was demonstrated that 1-adrenergic signaling is
necessary for hippocampus-dependent memory retrieval mediated by NE/E[92, 153]. In
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addition, I recently discovered that additional  receptors, including 2 and 3, influence
retrieval processes both individually and in conjunction with 1. Results by our lab
demonstrate that systemic administration or DH infusion of several 2 agonists (and a
partial 1 agonist with 2 activity) impair the retrieval of both IA and contextual fear
(Chapter 2-3). In part, this observation served as the impetus for a more detailed and
thorough examination of the roles of 2- and 3-adrenergic signaling in aversive memory.
Experiments accessing the function of 2 and 3 in learning are assisted by availability of
subtype selective receptor agonists and antagonists. Further, 2KO and 3KO animals
have been generated, enabling the utilization of both genetic and pharmacologic
approaches to study potential roles of 2 and 3 signaling in fear memory.

4.3 MATERIALS AND METHODS (see section 2.5, 3.3)
4.4 RESULTS & DISCUSSION
4.4.1 2 Signaling and Fear Memory
Accumulating evidence suggests that 2-adrenergic signaling plays a time-limited
role in the retrieval of hippocampus-dependent memory. 2KO mice express deficits in
contextual fear beginning as early as 30 min that last approximately 3-4 d, similar to the
time-course of impairment for NE, 1, cAMP, PKA and Epac signaling[92, 153] (Figure
4.1A). However, 2 signaling may be initially required at earlier times (~30 min after
acquisition) than when NE or 1 signaling is necessary (~2 hrs)[92] (Figure 4.1A). This
could be related to a deficit in the maintenance of short-term memory. Consistent with
this is the observation that systemic administration of a 2 antagonist (ICI) 30 min before
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training impairs contextual fear at 1 hr, but not 2 hrs post-conditioning (Figure 4.1B).,
indicating acquisition is not affected by blockade of 2 signaling. Interestingly,
administration of ICI 30 min post-training does not affect the expression of context fear
30 min later (Figure 4.1C), whereas ICI administered immediately after training impairs
freezing 1 hr later (Figure 4.1D). Thus, there appears to be a brief time window after
acquisition through which 2 signaling influences the expression of short-term memory
(STM). Additional studies are needed not only to confirm this result but also to address
whether administration of ICI pre- or post-training affects the acquisition or expression of
hippocampus-independent cued fear, a paradigm that controls for potential non-specific
effects of ICI on fear and motor performance.
Interestingly, retrieval deficits expressed by 2KOs dissipate completely at 5 days
and beyond, supporting a time-limited role for 2 signaling in intermediate-term retrieval
rather than in long-term acquisition or consolidation of aversive fear memory (Figure
4.1A). A ―spontaneous recovery‖ of contextual fear at later times is not consistent with
impaired consolidation, which would not be expected to recover, but is consistent with a
temporary impairment of memory retrieval. Further, 2KO and 12 DKO animals,
compared to their WT counterparts, express equivalent cued fear 1 d after training,
arguing against a general requirement for 2 signaling in fear memory consolidation
(Figure 4.1E). 2KO mice also express normal short and long-term retention of inhibitory
avoidance (IA), independent of training intensity (Chapter 2-3). IA would be impaired if
consolidation processes were affected. (Notably, however, 2 signaling can enhance the
consolidation of fear memory, analogous to increasing endogenous NE systemically or
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centrally within in the BLA, hippocampus or NTS[10, 11, 73, 78, 250][communications
with M. Ouyang and S.A. Thomas]).
Consistent with genetic results, pharmacologic evidence suggests that 2 signaling
plays a specific role in intermediate-term, aversive memory retrieval. Systemic
administration of ICI 118551, a selective 2 antagonist, 1 d after training dosedependently reduces contextual fear in control mice in a u-shaped fashion, with 10 g/kg
producing maximal impairment (Figure 4.1F). The extent and nature of the impairment
may be related to retrieval deficits induced by stress, GCs or 2 agonists (Chapter 2),
altering common effectors or signaling pathways influenced by 2 signaling. Future
studies are needed to address this. A u-shaped dose-response phenomenon may be
observed because low-moderate concentrations of ICI selectively bind to and change the
confirmation of the receptor, causing retrieval-mediated deficits whereas higher
concentrations of ICI also antagonize the 1 receptor, negating the compound’s
effectiveness in impairing retrieval. The discovery that CNS-based 1 and 2 signaling
can oppose one another is supported by multiple experimental outcomes, summarized as
follows: 1) 12 DKO mice, compared to control animals, equivalent levels of contextual
fear (Chapter 2); 2) Treatment with high-dose ICI 1d after training produces no affect on
the retrieval of IA (Chapter 2); 3) 2 agonist mediated retrieval deficits are likely ushaped because higher concentrations stimulate 1 receptors which support retrieval
(Chapter 2); and 4) selective stimulation of either 1 or 2 in the DH produce opposite
effects on cAMP signaling and combined stimulation of both receptors does not
significantly alter levels of cAMP (Chapter 2). In addition, direct infusion of ICI into the
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dorsal hippocampus 1d after training dose-dependently mirrors the affects of systemic
administration, with 50-200 ng producing disruption of contextual fear (communications
with M. Ouyang and S.A. Thomas). Consistent with genetic results, pharmacologic
evidence also supports a transient role for 2 signaling in CF retrieval. The time-course of
ICI impairment mirrors that of 2KOs, NE, 1, cAMP, PKA and Epac signaling (~2 hr –
4 days)[92, 153](Figure 4.1E). Future studies will determine if ICI administered 1 or 3 d
after training affects cued fear in WT animals. If it does not, this would support a
selective role for 2 signaling in hippocampus-dependent, retrieval-based processes. In
sum, genetic and pharmacologic data converge to convey a time-limited role for 2
signaling in the retrieval of hippocampus-dependent fear memory.
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Figure 4.1 2 Signaling & Fear Memory
(A) 2KO mice exhibit impaired contextual fear (CF) 30 min to 3 d post-conditioning, but not at
5 d and beyond. P < 0.001 for the main effect of genotype on freezing, P < 0.001 for the main
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effect of time on freezing and P < 0.001 for the interaction of genotype and time (410/group). * P < 0.05,

^ P < 0.01,

# P < 0.001 for post-hoc comparisons. (B) ICI

administration 30 min prior to conditioning impairs CF at 1 hr, but not 2 hrs post-injection. P <
0.05 for the main effect of treatment on freezing, P < 0.01 for the main effect of time on
freezing and P < 0.01 for the interaction of treatment and time (4-5/group). ICI was systemic
administered in all figures, unless otherwise noted. (C) ICI administration 30 min after
conditioning does not impair CF 30 min later (4-5/group). (D) ICI administration immediately
after training inhibits CF 1 hr post-injection. P < 0.01 for the main effect of treatment on
freezing (5/group). (E) 2KO and 12 DKO mice do not exhibit deficits in cued fear 1 d after
training, arguing against a general role for 2 signaling in freezing, fear or aversive memory
consolidation(4-5/group). (F) ICI, a 2 antagonist, dose-dependently inhibits CF 1 d after
training in WT mice. P < 0.01 for the main effect of dose (5/group). (G) WT mice receiving ICI
display deficits in CF 1 hr to 3 d post-conditioning, but not at 5 d. P < 0.001 for the main
effect of treatment on freezing, P < 0.09 for the main effect of time on freezing and P < 0.05
for the interaction of treatment and time (4-5/group).

Somewhat paradoxical is the result that 2 agonists and antagonists both
transiently impair the recall of fear memory (Chapters 2, 4). One could speculate this
occurs for a number of reasons. Signaling pathways and effectors affected by 2 signaling
may also influence retrieval processes in a U-shaped fashion. For example, inactivating
the receptor may change cAMP signaling or reduce signaling by other pathways (i.e.
ERK and/or PI3K) that are necessary for retrieval[251]. Conversely, overstimulation of
the receptor can decrease cAMP signaling, thus potentially decreasing signaling by other
effectors, including PKA, Epac and Rap2, which are required for retrieval[153](Chapter
2)(communications with M. Ouyang & S.A. Thomas). Alternatively, excessive activation
of 2 could cause hypersensitization and rapid internalization of the receptor[252] whose
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proper expression at the surface of the membrane may influence the ability to retrieve
information. Finally, altering 2 signaling could throw off a delicate balance necessary
between 2 and other  receptors in regulating retrieval processes.

4.4.2 Evidence for Coincident Signaling or Direct Molecular Interaction between
GR and 2-adrenergic Signaling in Aversive, Hippocampus-dependent Memory
Retrieval
Several lines of evidence suggest that the conformation of 2 receptor itself is
important to the retrieval process. For example, systemic administration or DH infusion
of a GR-antagonist 1d after training prevents 2 agonist-mediated impairment of
contextual fear (Figures 4.2A & 4.2B). Preliminarily, this would suggest that GR
signaling lies downstream of 2 signaling. However, co-administration of a 2 antagonist
completely mitigates GR agonist-induced impairment of both IA and contextual fear,
suggesting 2 signaling may be downstream of GR-signaling (Chapter 2). Taken together,
these results suggest either 1) coincident signaling by 2 and GR; 2) a direct molecular
interaction whereas conformational changes in GR can induce simultaneous changes in
the 2 receptor; or 3) that GR-like compounds can bind directly and activate or deactivate
the 2 receptor. The latter two possibilities seem more likely than the former because GCs
can impair retrieval in the absence of NE-signaling (Chapter 2). A direct molecular
interaction model is also supported by recent findings that insect ecdysteroids can directly
bind to and activate a dopamine GCPR that is most similar in sequence homology to 
adrenergic receptors[253]. However, a coincident signaling model cannot be excluded if
constitutive signaling by 2 receptor is the absence of ligand (NE) influences retrieval
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process. The observation that contextual retrieval deficits exhibited by NE-deficient mice
are reversed by administration of ICI is consistent with a role for constitutive signaling at
the 2 receptor (Chapter 2). Future studies will attempt to discriminate between
coincident signaling and direct molecular interaction models (5.2.3).
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Figure 4.2 GR Antagonists Prevent 2 Agonist-Mediated Disruption of HippocampusDependent Memory Retrieval
(A) Procaterol (2 Agonist) impairment of CF is reversed by co-administration of a GR
antagonist, Org 34850. P < 0.05 for the main effect of treatment on freezing (4-6/group).
Compounds were administered systemically. (B) DH infusion of procaterol inhibits CF, and
procaterol-induced deficits are prevented by co-infusion of a GR antagonist, RU486. P < 0.001
for the main effect of treatment on freezing (2-5/group). Infusions were administered 15 min
before testing 1 d after training.
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4.4.3 Putative Role of 3-adrenergic Signaling in Aversive, Hippocampus-dependent
Memory Retrieval
Initial evidence suggests that 3-adrenergic signaling can influence memory
retrieval. Systemic administration of a 3 antagonist (SR59230A) 1d after training dosedependently reduces contextual freezing in 12 DKO mice and a similar concentration of
SR likewise impairs retrieval in control animals (Figure 4.3A). Furthermore,
subcutaneous injection of the non-selective  blocker, propranolol, 1d after training
inhibits contextual retrieval in 12 DKO mice in a dose-dependent fashion, suggesting
propranolol’s affects are due (at least in part) to the antagonism of 3 receptors (Figure
4.3B). Notably, propranolol transiently impairs the retrieval of contextual fear and spatial
navigation but not cued fear in rats and control mice, suggesting it selectively influences
retrieval rather than consolidation processes[92]. Moreover, doses of SR59230A that
impair contextual fear do not significantly impair cued fear in control animals, suggesting
its effects on 3 are likely retrieval-based (Figure 4.3C). Additional evidence supports the
hypothesis that 3 signaling mediates retrieval processes. Co-administration of a 2
antagonist 1d after training in control mice readily reverses 3 antagonist-induced
impairment of contextual fear (Figure 4.3D). In addition, contextual memory deficits
exhibited 1d after training by 2KO mice are fully rescued by co-administration of a 3
antagonist (Figure 4.3D). Taken together, these results suggest a general role for 3 in
retrieval, because deficits created by inactivating 3 signaling can be prevented by
similarly reducing 2 signaling at a time after acquisition and consolidation have already
occurred. Molecular analysis of changes in hippocampal cAMP signaling induced by
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activation or inactivation of 3 signaling supports behavioral analysis that the receptor
functions in ways similar to 1[unpublished]. For instance, selective stimulation of either
1 or 3 receptors produces nearly equivalent increases in levels of cAMP[unpublished].
Chapter 5 discusses future experiments involving 3 signaling.
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Figure 4.3 3 Signaling Influences Hippocampus-dependent Memory Retrieval
(A) Administration of a 3 antagonist (SR59230A) impairs CF in 12 DKO and WT mice. P <
0.01 for the main effect of treatment on freezing (4-17/group).

Experiments in figure 4.3

were performed 1 d after training and systemic injections were administered 30 min before
testing. (B) Administration of the non-selective  antagonist propranolol reduces freezing in
12 DKO animals. P < 0.01 for the main effect of treatment on freezing (4-17/group). (C)
SR59230A does not impair hippocampus-independent cued fear in control mice (4-5/group).
(D) Co-administration of a 2 antagonist (ICI) prevents 3 antagonist-mediated inhibition of CF
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in WT mice. Likewise, freezing deficits exhibited by 2KO mice are reversed by administration
of a 3 antagonist. WT: P < 0.01 for the main effect of treatment on freezing. 2KO: WT: P <
0.01 for the main effect of treatment on freezing (3-24/group).

4.4.4 Combined Inactivation of 1, 2 and/or 3-adrenergic Signaling Influences
Aversive, Hippocampus-dependent Memory Retrieval
Initial evidence that inactivating all 3 -adrenergic receptors simultaneously
impairs hippocampus-dependent memory retrieval comes from studies using propranolol
to inhibit both contextual and spatial navigation[92]. Combined pharmacologic and
genetic approaches are being employed to access the respective contributions of multiple
receptor combinations to the retrieval process. For example, simultaneous coadministration of 1, 2 and 3 antagonists in control animals 1d after training
dramatically reduces contextual freezing (Figure 4.4). Likewise, co-injection of a 1 and
3 antagonist in 2KO mice produces similar levels of impairment whereas coadministration of a 2 and 3 antagonist in 1KO mice produces only moderate deficits
(Figure 4.4). Why the latter occurs is unclear, but likely depends on the net effect of
combined  antagonism on cAMP levels or other signaling pathways that influence
retrieval.
Interestingly, administration of a 2 antagonist in 1KO mice 1d after training
fully reverses contextual retrieval deficits whereas administration of a 3 antagonist does
not (Figure 4.4). This supports the hypothesis that 1 and 3 signal in a related fashion to
facilitate retrieval, and differently than that of 2. Of note, co-administration of a 1 and
3 antagonist in control mice does not impair contextual retrieval to a greater extent that
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individual antagonism of 1 or 3[92] (Figure 4.4), suggesting antagonism of either
receptor is sufficient to inhibit pathways needed for retrieval. On a different note,
subcutaneous injection of a 1 antagonist in 2KO mice partially restores contextual
freezing (Figure 4.4), supporting the idea that 1 and 2 signaling oppose each other in
retrieval. Why partial and not full rescue occurs is unclear but may be related to basal
signaling by the 2 receptor (or expression of 2 at the surface of the membrane) that is
important for retrieval. Future studies will continue to explore functions of  receptors in
fear memory and the intracellular signaling pathways they influence. In addition, regional
and subregion-specific floxed -AR mice will eventually assist in determining where in
the hippocampus (and in which cell types) individual -ARs are necessary for retrieval
(5.2.4).
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5.1 Summary
Evidence from the literature suggests that corticosteroid impairments in
hippocampus-dependent memory retrieval are mediated by GRs in a rapid, non-genomic
fashion. Consistent with this are our findings that 1) a selective GR agonist impairs
retrieval and 2) hippocampal infusion of a GC impairs retrieval within minutes after
administration. Interestingly, retrieval deficits induced by stress or administration of GCs
(or xamoterol) mimic effects of  agonists. Strikingly, effects mediated by stress or any
one of these agents are fully reversed by concurrent administration of a  antagonist (or
absent in KOs), suggesting that signaling by GR and are intimately linked. The
discovery that co-administration of a GR antagonist fully mitigates retrieval deficits
caused by a  agonist suggests that direct molecular interaction or coincident signaling
between GR and  is likely, and aggregate results demonstrate that GR or  signaling is
neither upstream nor downstream of one another. Pharmacogenetic experiments will
assist in distinguishing between these models (5.2.3).
Remarkably, all aforementioned agents appear to selectively affect hippocampusdependent memory retrieval, as these compounds produce no effect on the acquisition,
consolidation or expression of hippocampus-independent auditory fear memory.
Moreover, the actions of these compounds also appear to be mnemonic in nature because
these agents no longer affect memory expression 5 days after conditioning. In addition,
KOs express normal cued fear, a result consistent with the examined compounds that
effect signaling.
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Interestingly, GCs impair hippocampus-dependent memory retrieval in the
absence of NE, demonstrated by Dbh-/- mice displaying IA impairment after
administration of a GC shortly before testing. Our laboratory has shown that NE is
required for retrieval of contextual and spatial memory (as opposed to IA)[92, 93], so
confirming these results in additional DH-dependent tasks is difficult (as mice lacking
NE display deficits without GC treatment). It is possible that GC-mediated retrieval
impairment in NE/E-deficient mice results from developmental and/or compensatory
alterations in HPA function, adrenergic or GR signaling that contribute to the lack of a
phenotype. Adrenergic changes are unlikely, because memory deficits displayed by Dbh/-

mice (in the absence of GCs) are conditionally (and fully) reversed by acute

administration of L-DOPS[92].
Although GCs can impair retrieval in the absence of NE, stress-mediated retrieval
deficits require both NE and  signaling, supported by the finding that stressed Dbh-/and KO mice show significantly less IA impairment when compared to controls. The
observation that NE is required for stress, but not for GC-mediated effects is consistent
with the idea that stress enhances the release of several compounds in addition to GCs
(e.g. NE) than may synergize with GCs to produce retrieval deficits. Moreover, restraint
stress, compared to GC administration, results in a 5- to 7- fold lower rise in plasma
levels of cort, supporting the notion that other factors besides GCs contribute to the stress
response. Conversely, a lack of stress-induced retrieval inhibition displayed by Dbh-/mice could be due to developmental or compensatory alterations in HPA function,
adrenergic or GR signaling, and a future experiment will test this hypothesis. If stress110

mediated deficits displayed by Dbh-/- are retrieval-based, it can be predicted that
administering L-DOPS prior to stress should fully reverse the phenotype (e.g. KO
retrieval will be impaired at levels similar to WT). Such a result would argue against
developmental effects of the mutation accounting for GC impairment is the absence of
NE.
Selective stimulation of signaling reduces levels of DH cAMP ex-vivo and
retrieval deficits induced by either stress, GCs, agonists or xamoterol are blocked by
expression of pertussis toxin in the DH, suggesting these agents also operate by
decreasing cAMP signaling. To confirm and extend these results, DH cAMP will be
measured in control and KO slices after application of GCs (or xamoterol) (5.2.1). The
prediction would be that these agents would reduce levels of cAMP in controls, and cause
little or no reduction in KOs. In addition, a cAMP activating analog will be infused into
the DH of WT mice to determine if enhancing cAMP signaling prevents retrieval deficits
induced by stress, GCs, agonists and xamoterol.
Initial evidence suggests that  and  receptors can influence retrieval,
independent of GCs. The finding that KOs and ICI-treated controls display contextual
fear impairments at 1-3, but not 5 or more days after conditioning suggest a specific role
for signaling in intermediate-term, hippocampus-dependent retrieval. To further
support this hypothesis, ICI will be administered to controls prior to testing cued fear 1 or
3 days after conditioning. A requirement for  in either the acquisition or long-term
consolidation of fear memory would be unlikely if ICI-treated animals exhibit
unimpaired auditory fear at these times. -ARs may also play a fleeting role in short111

term memory, which is supported by the findings that administration of ICI 30 min prior
to or immediately after training impairs contextual fear expression at 1 h, while injection
of ICI 30 min before training does not affect CF expression at 2 h (Figure 4.1). The later
result suggests the deficit is in the maintenance rather than the acquisition of memory and
is generally consistent with KOs displaying impaired CF at early time points. In
addition, the observation that administration of ICI 30 min after training does not impair
CF at 1 h (in WT mice) argues against a deficit in short-term memory retrieval.
Furthermore, it can be predicted that administering ICI immediately after training will not
impair CF expression at 2 h (in WT animals), which would provide additional evidence
that impairments in STM are not due to deficits in acquisition.
Preliminary data from pharmacologic and genetic experiments suggest that 
signaling may be required for retrieval. Additional studies will access the time course of
impairment mediated by 3 signaling in WT mice. If deficits created by blocking 3
signaling are time-dependent in nature (as they are for other receptors)[1](Chapter 2),
this would support a role for the receptor in intermediate-term retrieval rather than in
acquisition or long-term consolidation. Future studies will examine 3KO animals (and
control littermates) in order to assign a more definitive role for 3 in fear learning.
Moreover, testing cued fear in KOs will be important in determining whether freezing
deficits caused by the lack of  signaling are hippocampus/retrieval-based or nonspecifically effect levels of fear or freezing.
Despite the findings that both non-selective and subtype-selective  antagonists
impair retrieval, several outcomes support the importance of distinguishing between
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receptor subtypes. For example, behavioral, pharmacological and molecular evidence
suggests that hippocampal - and -ARs fundamentally oppose one another in retrieval,
and initial data suggests a similar dichotomy might exist between - and -ARs.
Finally, the failure of non-selective antagonists to significantly reduce the retrieval of
traumatic memories in PTSD may be due to negating effects caused by combined
receptor antagonism.
Results in vivo and ex-vivo demonstrate that -coupled Gi/o signaling suppresses
levels of cAMP signaling needed for retrieval of aversive, hippocampus-dependent
memories (Chapter 2).  and GR agonist effects on retrieval mirror those of other agents
that similarly reduce levels of cAMP, PKA and/or PKA-Epac signaling[153].
Importantly, Gi/o  and  subunits signal through proteins other than adenylate
cyclase[254](Figure 5.1), and some these effectors may be involved in pathways
necessary for episodic memory recall. For example, signaling by Gi/o  alters the activity
of calcium/potassium ion channels and phospholipases[254]. Likewise, GTP binding of
Gi/o  (induced by  agonist or possibly GC activation of -ARs) results in the
dissociation of  subunits, which exert effects on ACs, ion channels, PLC PI3K and
other molecules[254]. Accumulating evidence demonstrates that many of these effectors
can influence the recall of hippocampus-dependent memory. For example, calcium
channel blockers (e.g. verapamil) dose-dependently rescue contextual retrieval deficits in
mice lacking NE/E while calcium channel agonists (e.g. Bay K) inhibit retrieval in WT
animals (communications with S.A. Thomas). Moreover, PLCmice display deficits
in contextual fear 1d after training, consistent with either impaired consolidation or
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retrieval[255]. In addition, CA1 infusion of either of two PI3K inhibitors 48 hr after
training diminish contextual freezing[251]. These inhibitors also reduce the activity of
ERK, which also may be necessary for retrieval[251]. As a whole, such results support
the probability that context-spatial retrieval is regulated by multiple signaling pathways
that may act in concert, parallel or separately to effect the recall of fear-based information
necessary for survival. Thus, redundancy in DH signaling processes influencing retrieval
is of likely evolutionary benefit. The finding that multiple neurotransmitter and
adrenergic receptors couple either to Gs, Gi/o and/or both support the importance of Gprotein signaling in retrieval[254], with NE/E serving as a critical modulator[92]. Adding
to the complexity are the many isoforms of G, and expressed in the
hippocampus[256], which may ultimately combine in similar or different ways to
regulate retrieval.
The observations that GCs rapidly impair contextual retrieval, that protein
synthesis inhibitors do not prevent GC induced spatial deficits and that proteinconjugated cort impairs hippocampus-dependent memory all support non-genomic effects
of GCs in influencing retrieval[131, 204](Chapter 2), some of which may be mediated by
intracellular signaling through membrane-bound GR receptors[200, 201]. Interestingly,
moderate to high levels of stress/GCs increases mGR-induced calcium channel, PLC and
GABAA activity and reduces NMDA receptor signaling[200, 201]. Notably, GABA
agonists administered ICV or into the DH impair retrieval[237], mimicking the effects of
stress and glucocorticoids, while NMDA antagonists produce no effect of hippocampusdependent memory recall[257]. It is possible that similar isoforms of and  subunits
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localized with mGRs and 2-ARs converge on common effectors, such as phospholipase
C to influence processes relating to fear memory. For example, PLC agonists dosedependently enhance the consolidation of auditory fear memory (communications with
S.A. Thomas) and may impair the retrieval of fear memory in WT animals, analogous to
how GCs display opposing effects on consolidation and retrieval that are concentrationdependent. Future experiments will test this hypothesis. There also exists the possibility
that NE binds to mGRs, concurrently regulating GR activity along with the activity of 2ARs. Additional experiments are needed to test this possibility.
Alternatively, NE could directly interact with mGRs, changing their confirmation,
increasing the affinity of mGRs for GCs (relative to MRs) and/or lowering the
concentration of GCs needed to impair retrieval. Importantly, peripheral administration of
the adrenal steroid synthesis inhibitor, metyrapone completely blocks the deleterious
effects of stress and GCs on spatial memory retrieval[123]. Such results suggest
(indirectly) that GCs are not readily located in pools within the CNS, but are rapidly
recruited during stress from the periphery to impair retrieval and promote consolidation
of a newer, more salient stressful event. Of note, plasma cort levels peak 30 min
following a stressful event, at a time associated with maximal retrieval impairment[123].
In contrast, cort is not significantly elevated 2 min or 4 hrs after stress, correlating to
times when animals do not display cognitive deficits[123]. In contrast, levels of
extracellular NE in the CNS reach a zenith 10-15 minutes after a stressor, faster than that
of GCs[123, 258]. This raises the prospect that NE bound to either 2-ARs or mGRs
helps directs the effects of GCs on retrieval. The finding that GCs released during low115

moderate restraint stress do not impair retrieval in mice lacking NE (but in WT) support
the observation that NE priming of adrenergic and/or GR signaling might be critical in
observing GCs effects, at least in some cases. The failure GCs to significantly reduce
cAMP signaling both in vitro and ex vivo suggest that, under some physiological
conditions, basal NE activity might be critical to observe GCs/stress effects. Mice lacking
hippocampal GR will likely play an important role in distinguishing between some of
NE’s potential effects on GRs and 2-ARs. Fortunately, there are a growing number of
methods to regionally, conditionally and/or temporarily reduce, eliminate or upregulate
GR and/or 2-AR expression and the combined use of pharmacological and genetic
approaches will ultimately play an important role understanding the complex interactions
between stress, GCs and 2 signaling.
Unfortunately, IHC, ISH and radioligand studies have been inconsistent
concerning the extent of GR and -AR localization within specific subfields of the
hippocampus and amygdala[96-98, 100, 101, 197]. Recent reports suggest that
hippocampal and amygdalar GRs and 2-ARs are localized within the membrane, cytosol
and nucleus, while 1-ARs are limited to the membrane and cytosol[96, 194].
Understanding such information might have function significance for both the
consolidation and retrieval of hippocampus-dependent fear memories. For example, GR,
1-AR and or 2-ARs subcellular localization could change rapidly during times of stress,
favoring processes that support consolidation while opposing those needed for retrieval.
For example, 2-ARs (or GRs) may be recruited to hippocampal membranes while 1ARs may be sequestered away from the membrane, both of which may negatively impact
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retrieval. It would also help explain the supersensitivity of 2 agonists in the presence of
GCs. Alternatively, factors influenced by stress or GCs could increase nuclear levels of
2-ARs (or GRs) in the BLA which could bind GREs (or 2-AR response elements?),
serving to regulate the expression of genes critical for learning (e.g. PKM-Arc, c-fos).
For example, administration of cort immediately after IA training increases hippocampal
Arc expression 45-60 min later, which can be blocked by co-administration of a nonselective -antagonist[258]. Interestingly, mice lacking NE show impaired Arc in CA1
the 30 min following retrieval[259], suggesting that GC-adrenergic interactions might be
critical for the expression of IEGs at particular times during various stages of fear
learning. Similarly, the possibility of nuclear 2 localization raises the possibility that 2
and GR might form heterodimers in the cytosol or nucleus that regulate consolidation
through the recruitment or repression of various transcription factors.
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Figure 5.1 Effectors of 2-coupled, Gi/o Signaling (Adapted from Wettschureck et al.,
Physiol Rev, 2005. 1159-204).

5.2 Future Directions
This section describes experiments and alternative approaches that can be used to
further explore the interactions between GCs, GRs, 2-ARs and cAMP signaling and
between -AR subtypes.
5.2.1 Ex-Vivo Application of  and GR Agents in Control and AR KO Mice to
Determine Effects on DH cAMP Signaling
Chapter 2 assesses contributions of individual receptors to DH cAMP signaling
using ex-vivo slice preparation. Future studies will use this technique to explore how
stress and GCs affect levels of DH cAMP in control and KO animals. Because
selective stimulation of  decreases levels of cAMP, it is likely that stress and GCs will
118

reduce levels of cAMP in WT animals and have less effect in mice lacking -ARs. It can
also be predicted that co-administration of a antagonist will prevent the decline in
cAMP signaling mediated by GCs, analogous to initial results demonstrating that ICI
blocks the reduction in cAMP signaling caused by stimulation of [unpublished].
Moreover, if  receptors are required for retrieval and mediate their effects by enhancing
cAMP signaling, administration of a either a or antagonist should reduce DH cAMP
levels in WT mice and have less effect in mice lacking - or -ARs. Furthermore,
pharmacologic and genetic manipulation of multiple  receptors will access combinatory
effects on DH cAMP signaling.
Advantages of this method are that cAMP manipulation occurs in a highlycontrolled environment, not impacted by the activity of the animal or cAMP signaling
from adjacent brain regions. Disadvantages of this technique are the artificial
environment in which the tissue is maintained and that acute cAMP levels can be affected
by decapitation or damaged tissue that accompanies slice preparation. Such effects are
minimized by perfusing DH slices (of unanaesthetized animals) for 1 h before
pharmacologic manipulation. Ex-vivo results can be confirmed by in vivo microdialysis,
a technique that possesses some advantages.

5.2.2 In-Vivo Microdialysis to Measure Extracellular cAMP in Naïve and
Conditioned Animals Following DH Infusion of AR & GR Compounds
Microdialysis has been used to measure extracellular cAMP in the CNS after
administration of stress and agents affecting both  and GR signaling[260, 261].
Although most cAMP resides intracellularly, a measurable fraction is released
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extracellularly following an aversive event or after systemic/central manipulation of
adrenergic or GR signaling[260, 261]. Unlike ex-vivo experiments, levels of cAMP can
be measured in real time in both naïve and fear conditioned animals (e.g. measuring
cAMP before, during and after retrieval of fear memory). Perhaps the most compelling
reason to perform microdialysis is that or GC effects on cAMP levels might differ
using in-vivo and ex-vivo analysis[3]. For example, corticosterone produces a 40%
reduction in extracellular cortical cAMP measured in vivo, but produces much less of an
effect in cortical slice preparations[3]. Hence, achieving consistent results across
preparations would be the gold-standard in cAMP analysis.
Several outcomes can be predicted using microdialysis. One prediction is that
administration of a GC,  agonist, or  antagonist shortly before testing may impair
levels of DH cAMP signaling that are required for retrieval. Similar pharmacologic
manipulation may also reduce cAMP levels in unconditioned animals. In addition, DH
cAMP levels might rise following retrieval in untreated animals, contributing to the
reconsolidation or extinction of fear memory. Moreover, it can be hypothesized that coadministration of a  antagonist shortly before testing retrieval will prevent the decline
in DH-cAMP mediated by concurrent GC or  agonist administration. Conversely, coapplication of a GR antagonist should prevent a  agonist-mediated decrease in cAMP
levels.
There are caveats to using in-vivo methods as well. Efforts need to be made to
discriminate between alterations in DH-cAMP signaling that occur from behavioral,
pharmacologic and non-specific effects (e.g. changes in the environment prior to
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manipulation that impact levels of anxiety or activity). Also, implantation of probe causes
necrosis and long-lasting molecular changes induced by apoptotic or inflammatory
processes may affect cAMP levels, producing outcomes that differ from ex-vivo
experiments.
5.2.3 Use of GRfl/fl X CaMKII-Cre+ Mice to Distinguish Between Direct Interaction or
Coincident Signaling Between GR & -AR
The CRE-lox P system provides a method for excising genes in specific cell types
and/or brain regions. For example, floxed GR mice lacking GR expression in forebrain
excitatory neurons have been developed (GRfl/fl X CaMKII-Cre+)[262, 263]. Moreover,
lines that selectively express Cre in specific subfields within the hippocampus (e.g. CA1,
CA3, DG) are available (CaMKII-Cre+, KA1-Cre+, POMC-Cre+)[263-265]. Using
GRfl/fl X CaMKII-Cre+ mice may assist in distinguishing between coincident signaling
and direct interaction models to account for how GR & signaling intersect to impair
retrieval. First, GRfl/fl X CaMKII-Cre+ mice will be tested to determine if they display
retrieval deficits. It is not predicted that animals would display such impairments,
because infusion of a GR antagonist into the hippocampus does not reduce retrieval in
WT mice. Most previous experiments have utilized corticosterone (a non-selective GR
agonist) to assess GC involvement in retrieval, so cort will be administered to GRfl/fl X
CaMKII-Cre+ mutants to examine whether cort-induced retrieval deficits require GR.
Because a selective GR antagonist blocks cort-mediated retrieval impairment in WT
animals, it is likely that GR is necessary for cort’s effects on retrieval.
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If GR is required for cort-mediated deficits, hippocampus subfield-specific
GRKOs will be employed to determine which hippocampal regions mediate GR effects.
In addition, hippocampal homogenates from floxed and WT mice will be subjected to coimmunoprecipitation (co-IP) to determine if GR and  might interact (directly or through
an intermediary) at the molecular level.
If GR is necessary for cort effects on retrieval, it will also be determined if effects
of  agonists also depend on GR. If a agonist does not impair retrieval in GRfl/fl X
CaMKII-Cre+ mice, this favors a coincident signaling model because concurrent GR
signaling would be necessary for  effects. Alternatively, if a agonist impairs retrieval
in mice lacking hippocampal GR, this suggests that there might be a direct interaction
between  and GR, in order to explain why a GR antagonist blocks the effects of a 2
agonist in WT mice. To test this idea further, the ability of a GR antagonist to block the
effects of a 2 agonist would be examined in GRfl/fl X CaMKII-Cre+ mice.
Conversely, GR may not be relevant for cort-induced impairment of retrieval.
Several possibilities could account for such a result. For example, GR may not be
eliminated in all hippocampus subfields or cell types that are important for retrieval. For
example, GR excision could be incomplete (performing either ISH or IHC on GR
mutants and comparing GR expression to WT mice would serve as an important control).
Another possibility is that GR located in glial or inhibitory neurons mediates retrieval
deficits. In addition, cort could activate proteins other than GR (e.g. MR) that play a role
in retrieval. Alternatively, cort-mediated retrieval deficits might depend on direct
interaction between cort and -ARs. One could test this possibility by performing a
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saturated binding assay in which 3H-cort is administered to -transfected HEK-293,
CHO or SF9 cells, which possess little or no GR expression[266-268]. If results suggest
that cort interacts with the  receptor, a competitive binding assay will be used to
determine if cort acts specifically at the NE/E binding site.
5.2.4 Use of Floxed R Mice to Examine Hippocampal Subfield-specific
Contributions of  Signaling in Retrieval
Floxed mice for hippocampal  are being developed (β1fl/f) (S.A. Thomas).
Efforts are planned to create similar floxed  and mice. Such mutants can be used to
confirm pharmacologic and conventional mutant data indicating that hippocampal
signaling by all 3 Rs may be necessary for retrieval, and more importantly, in what
regions of the hippocampus individual Rs might be required. effects could arise
from signaling in excitatory or inhibitory neurons or glia, and that all three possibilities
will be tested by crossing floxed mice with cell-type specific Cre driver lines such as
CaMKII-Cre+, GAD67-Cre+ and GFAP-Cre+[263, 269, 270]. It will be necessary to
determine the specificity and extent of regional and subfield  receptor ablation in floxed
 mice crossed with various Cre-expressing mice using ISH or IHC. Conventional -KOs
will provide important controls for the specificity and extent of these techniques.
Evidence suggests that CA1 is critical in contextual and spatial memory
retrieval[271, 272]. Interestingly, NE/E-deficient mice exhibit CA1-selective deficits in
Arc and Fos expression following retrieval and CA1 Fos expression is similarly impaired
in KOs[259, 273]. It can be predicted that CA1 might also be critical for and 
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effects, and the use of subfield-specific KOs will assist in determining the regions where
individual ARs may converge to influence retrieval.
5.2.5 Intracellular Recording from CA1 Pyramidal Neurons to Examine if -cAMP
& GR Signaling Mediate Voltage-gated Calcium Channel Effects on the Slowafterhypolarization (sAHP)
It is well established that synaptic plasticity in the hippocampus, including CA1
pyramidal neurons, is critical for contextual and spatial memory consolidation[274].
Interestingly, enhanced cAMP-PKA signaling is believed to contribute to the reduction in
the sAHP that occurs following conditioning in aversive, hippocampus-dependent
tasks[275, 276], and may lead to a similar decline during retrieval. Notably, naive NE/Edeficient mice do not express deficits in either basal synaptic CA1 physiology or in the
early or late phases of LTP[1], consistent with evidence indicating that NE is not required
for consolidation of hippocampus-dependent memory[1]. On the other hand, -ARs can
alter cAMP-PKA signaling in the DH (Chapter 2), which can influence the activity of
voltage-gated, Ca++ channels (VGCCs) that are known to mediate the sAHP[277].
Blockade of VGCCs with calcium channel blockers reduce the slow phase of the AHP,
decreasing the time between action potentials (APs), decreasing accommodation and
promoting LTP (by increasing the rate of neuronal firing), similar to the effects of a NE,
1 agonists and cAMP-activating analogs on the sAHP[278-280]. Interestingly, all these
agents facilitate the retrieval of hippocampus-dependent memory[92, 153][unpublished].
Conversely, cAMP antagonists, GCs, stress and Ca++ channel agonists enhance the
activity of VGCCs, increasing the sAHP[280-283]. Notably, our lab has shown that all of
these treatments impair the retrieval of fear memory [153](Chapter 2)[unpublished].
124

Hence, intracellular recording will be utilized to explore the hypothesis that 2 agonists
mediate their effects by enhancing Ca++ signaling and increasing the sAHP, which may
prevent the neuronal activation in CA1 required for retrieval. In addition, future
experiments will test if 2 antagonists prevent GC and stress mediated enhancement of
the sAHP, similar to GR antagonists[282]. A positive outcome would support the
hypothesis that 2-AR and GR signaling mediate their effects through similar
mechanisms, perhaps through VGCC modulation of the sAHP. If so, a 2 or GR
antagonist should prevent enhancement of the sAHP mediated by a VGCC agonist.
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